[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 140
1. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei arising from colonic polyps.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • RESULTS: In a review of the clinical management of these patients, all three had an event whereby neoplastic cells from the surface of the colonic polyp could have gained access to the free peritoneal cavity.
  • CONCLUSIONS: Colonic polyps can serve as a source of dysplastic cells whereby pseudomyxoma peritonei can result.
  • Caution to prevent seeding to the free peritoneal cavity during surgery for colonic polyps should be observed.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / etiology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Ohta Y, Saitoh K, Akai T, Uesato M, Ochiai T, Matsubara H: Early primary duodenal carcinoma arising from Brunner's glands synchronously occurring with sigmoid colon carcinoma: report of a case. Surg Today; 2008;38(8):756-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early primary duodenal carcinoma arising from Brunner's glands synchronously occurring with sigmoid colon carcinoma: report of a case.
  • We herein report a case of early primary duodenal carcinoma arising from Brunner's glands synchronously occurring with sigmoid colon carcinoma.
  • A 65-year-old man with a 5-year history of diabetes mellitus and benign prostatic hypertrophy was admitted to our hospital to undergo a resection of sigmoid colon carcinoma in December 2000.
  • Upper gastrointestinal endoscopy, which was performed as routine preoperative screening, revealed an elevated submucosal-tumor-like lesion with a shallow central depression in the anterior wall of the duodenal bulb.
  • The histopathology of the resected duodenal specimen revealed the tumor to be an adenocarcinoma arising from Brunner's glands.
  • [MeSH-major] Brunner Glands / pathology. Brunner Glands / surgery. Colon, Sigmoid / pathology. Colon, Sigmoid / surgery. Colonic Neoplasms / surgery. Duodenal Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1994 Mar-Apr;40(2 Pt 1):233-6 [8013831.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1442-8 [16224210.001]
  • [Cites] J R Soc Med. 1986 Mar;79(3):173-4 [3701756.001]
  • [Cites] J Gastroenterol. 2002;37(4):293-6 [11993514.001]
  • [Cites] Gastroenterol Jpn. 1993 Feb;28(1):118-25 [8382639.001]
  • [Cites] Histochem J. 1991 Jan;23(1):22-8 [1718927.001]
  • [Cites] Postgrad Med J. 2003 Jul;79(933):416-7 [12897224.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):655-9 [12070607.001]
  • (PMID = 18668323.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 14
  •  go-up   go-down


3. Merenda R, Portale G, Galeazzi F, Tosolini C, Sturniolo GC, Ancona E: Pancreaticoduodenectomy for dysplastic duodenal adenoma in a patient with familial adenomatous polyposis. Tumori; 2008 Nov-Dec;94(6):882-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal polyposis is the main feature of familial adenomatous polyposis (FAP), but benign and malignant lesions have also been described in the stomach, duodenum, small bowel, biliary tract and pancreas.
  • This report described the rare case of a patient presenting with duodenal adenomas with dysplastic changes and tumor infiltration as the first sign of FAP, who was treated by pancreaticoduodenectomy followed by proctocolectomy for subsequent dysplastic changes in colonic polyps.
  • [MeSH-major] Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Colonic Polyps / pathology. Duodenal Neoplasms / surgery. Pancreaticoduodenectomy


Advertisement
4. Nowicki MJ, Bishop PR, Subramony C, Wyatt-Ashmead J, May W, Crawford M: Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion. J Pediatr Gastroenterol Nutr; 2005 Nov;41(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion.
  • Colonic polyps are common both in adults and children; however, the malignant potential varies according to the type of polyp.
  • To determine whether CSM represents a preneoplastic lesion, we studied endoscopic colonic mucosal biopsies for markers of cell replication (Ki-67) and malignant transformation (p53) in mucosal biopsies of CSM, normal colonic tissue, tubular adenomas, and adenocarcinomas.
  • The degree of Ki-67-positive staining cells was similar for CSM and normal colonic tissue, whereas there was significantly increased staining for both tubular adenomas and adenocarcinomas.
  • There was no evidence of p53 staining in CSM and normal colonic mucosa, whereas there was varying degrees of staining in tubular adenomas and adenocarcinomas.
  • The association of CSM with benign juvenile polyps and the absence of histologic markers for increased replication and malignant transformation support the notion that this endoscopic finding is not preneoplastic.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Intestinal Mucosa / pathology. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Child. Child, Preschool. Colon / pathology. Colonoscopy. Female. Humans. Immunohistochemistry. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254516.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


5. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol; 2010 Jan;41(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
  • We performed immunohistochemistry for napsin A and thyroid transcription factor-1 using tissue microarrays of 95 adenocarcinomas, 48 squamous cell carcinomas, 6 neuroendocrine tumors of the lung, as well as 5 colonic, 31 pancreatic, and 17 breast adenocarcinomas, 38 malignant mesotheliomas, 118 renal cell carcinomas, and 81 thyroid tumors.
  • The tissue microarrays also included 15 different benign tissues.
  • There were 13 napsin A-positive/thyroid transcription factor-1-negative and 2 thyroid transcription factor-1-positive/napsin A-negative tumors, increasing the number of cases that were positive with at least one of the markers to 81 (85%) of 95.
  • The limited number of neuroendocrine tumors tested was napsin A negative.
  • All squamous cell carcinomas, adenocarcinomas of the colon, pancreas and breast, and mesotheliomas were negative for both markers.
  • Of the renal tumors, napsin A was positive in most of papillary renal cell carcinomas (79%), about one third (34%) of clear cell renal cell carcinomas, and in a single case of chromophobe renal cell carcinoma (3%).
  • As expected, all renal tumors were thyroid transcription factor-1 negative, and all thyroid tumors, except for one papillary carcinoma, were thyroid transcription factor-1 positive.
  • The combined use of napsin A and thyroid transcription factor-1 results in improved sensitivity and specificity for identifying pulmonary adenocarcinoma in primary lung tumors and in a metastatic setting.
  • [MeSH-major] Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Nuclear Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pancreatic Neoplasms / metabolism. Thyroid Neoplasms / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2012 Jul;43(7):1153-4; author reply 1154 [22703591.001]
  • (PMID = 19740516.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


6. Brouland JP, Gélébart P, Kovàcs T, Enouf J, Grossmann J, Papp B: The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol; 2005 Jul;167(1):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis.
  • To better characterize the role of SERCA3 in colon carcinogenesis, its expression has been investigated in colonic epithelium, benign lesions, adenomas, and adenocarcinomas.
  • We report that SERCA3 expression increased along the crypts as cells differentiated in normal colonic mucosa and in hyperplastic polyps, was moderately and heterogeneously expressed in colonic adenomas with expression levels inversely correlated with the degree of dysplasia, was barely detectable in well and moderately differentiated adenocarcinomas, and was absent in poorly differentiated tumors.
  • Inhibition of Sp1-like factor-dependent transcription blocked SERCA3 expression during cell differentiation, and SERCA3 expression was induced by the expression of dominant-negative TCF4 in colon cancer cells.
  • These data link SERCA3 expression to the state of differentiation of colonic epithelial cells, and relate SERCA3 expression, already decreased in adenomas, to enhanced adenomatous polyposis coli/beta-catenin/TCF4-dependent signaling and deficient Sp1-like factor-dependent transcription.
  • In conclusion, intracellular calcium homeostasis becomes progressively anomalous during colon carcinogenesis as reflected by deficient SERCA3 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Calcium / metabolism. Calcium-Transporting ATPases / biosynthesis. Colonic Neoplasms / enzymology. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Blotting, Western. Cell Line, Tumor. Cell Transformation, Neoplastic. Colonic Polyps / enzymology. Cytoskeletal Proteins / genetics. DNA-Binding Proteins. Endoplasmic Reticulum / metabolism. Humans. Immunohistochemistry. Sarcoplasmic Reticulum Calcium-Transporting ATPases. TCF Transcription Factors. Trans-Activators / genetics. Transcription Factor 7-Like 2 Protein. Transcription Factors. Transfection. Transgenes. beta Catenin

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):82-92 [10384103.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Gene. 1999 Nov 29;240(2):261-7 [10580145.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14483-9 [1385815.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):G371-9 [1415549.001]
  • [Cites] Cell Calcium. 1993 Jul;14(7):531-8 [8402836.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2916-21 [7504695.001]
  • [Cites] Am J Med Sci. 1994 Mar;307(3):167-72 [8160706.001]
  • [Cites] J Mol Recognit. 1994 Sep;7(3):189-97 [7880543.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6 [8629105.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):299-306 [8825032.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10746-50 [9099725.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22199-206 [9268365.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):111-4 [9384695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1371-6 [10625687.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:195-9 [10667218.001]
  • [Cites] Science. 2000 Apr 14;288(5464):331-3 [10764645.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):203-7 [10913614.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):926-9 [10963297.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):795-804 [10996197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G806-14 [11005769.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):570-6 [11212251.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2413-22 [11259590.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):329-42 [11308031.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25742-52 [11337508.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):249-56 [11812948.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):122-8 [11943137.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16673-81 [11872750.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26310-20 [11986315.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):307-15 [12123752.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36471-8 [12119294.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):147-52 [12387883.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3245-53 [12401716.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45579-91 [12207029.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):269-78 [12543089.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):279-305 [12543090.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):405-11 [12543099.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):665-77 [12581631.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):107-17 [12633551.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3220-8 [12515718.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1861-2 [12692187.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):445-54 [12729578.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17785-91 [12624107.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):399-409 [12790808.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6023-31 [12955081.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47877-89 [12975374.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1041-3 [14647298.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43 [15047174.001]
  • [Cites] Curr Mol Med. 2004 May;4(3):313-22 [15101688.001]
  • [Cites] Annu Rev Biochem. 2004;73:437-65 [15189149.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1223-36 [15336970.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):687-98 [6476197.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1988 Jul;51(4):746-51 [3144112.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5447-59 [2548163.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13982-94 [9593748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60 [9707565.001]
  • [Cites] Biochim Biophys Acta. 1999 Jan 18;1444(1):85-91 [9931450.001]
  • [Cites] Nutr Rev. 1999 Apr;57(4):124-6 [10228349.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):779-85 [10353711.001]
  • (PMID = 15972967.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Trans-Activators; 0 / Transcription Factor 7-Like 2 Protein; 0 / Transcription Factors; 0 / beta Catenin; EC 3.6.3.8 / ATP2A3 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1603437
  •  go-up   go-down


7. Shantha Kumara HM, Hoffman A, Kim IY, Feingold D, Dujovny N, Kalady M, Luchtefeld M, Whelan RL: Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels. Surg Endosc; 2009 Feb;23(2):409-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.
  • INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are increased after surgery and may stimulate tumor growth after cancer resection.
  • This study's purpose was to determine the impact of open and minimally invasive (MIS) colorectal resection (CR) for benign indications on plasma Ang 1 and 2 levels.
  • CONCLUSION: CR for benign pathology results in higher Ang 2 levels, lower Ang 1 levels, and lower Ang 1 to Ang 2 ratios early after surgery.
  • These results, plus the already noted VEGF increases, suggest that surgery results in proangiogenic plasma protein changes that may stimulate tumor growth early after surgery.
  • [MeSH-major] Angiopoietin-1 / blood. Angiopoietin-2 / blood. Colectomy. Colonic Diseases / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Surg Endosc. 2009 Feb;23(2):416. Kallady, M [corrected to Kalady, M]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] J Pathol. 2004 Sep;204(1):1-10 [15307132.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):659-70 [11166279.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):2-9 [10664112.001]
  • [Cites] World J Surg. 1996 May;20(4):460-4 [8662135.001]
  • [Cites] J Lab Clin Med. 2005 Apr;145(4):194-203 [15962838.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [Cites] Science. 1998 Oct 16;282(5388):468-71 [9774272.001]
  • [Cites] Biochem Pharmacol. 2001 Feb 1;61(3):253-70 [11172729.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1670-4 [15540297.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):361-73 [11310829.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • (PMID = 18813991.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2
  •  go-up   go-down


8. Moussi A, Nouira R, Bourguiba B, Daldoul S, Zaouche A: A rare cause of lower gastrointestinal bleeding. Tunis Med; 2010 Dec;88(12):961-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyoma of the colon are rare benign smooth muscle tumours.
  • The colonoscopy showed an active bleeding from the right colon but it was enable to specify the nature and the exact seat of the bleeding lesion.
  • An emergent operation showed a tumor of the right colic angle of 8 cm.
  • CONCLUSION: Colic leiomyomas are rare benign tumours.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Gastrointestinal Hemorrhage / etiology. Leiomyoma / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21136371.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


9. Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C: Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene; 2006 Jan 26;25(4):599-608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
  • We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Lithostathine / genetics. Liver Neoplasms / genetics. Mutation. beta Catenin / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Cell Line, Tumor. Colonic Neoplasms / genetics. Hepatoblastoma / genetics. Humans. Male. Signal Transduction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314847.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / REG1A protein, human; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


10. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Although there are examples in the literature of high grade PC that stain focally with some of the basal cell markers, these cases are usually readily diagnosed based on H&E appearances and are unlikely to be confused with these benign mimickers.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • The use of AMACR/basal cell antibody cocktails has been found to greatly facilitate the distinction between PC and its benign mimickers, especially when only limited tissue is available for staining.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • CDX2 and villin are useful markers to diagnostically separate colonic adenocarcinoma from PC.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis


11. Fine JL, Kagemann L, Wollstein G, Ishikawa H, Schuman JS: Direct scanning of pathology specimens using spectral domain optical coherence tomography: a pilot study. Ophthalmic Surg Lasers Imaging; 2010 Nov-Dec;41 Suppl:S58-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Low-magnification features were recognizable, including tissue outlines, fat, vessels, and outlines of colonic mucosal crypts.
  • Subtle textures that were suggestive of benign breast lobules and ovarian tumor features were also visible.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • [Cites] J Biomed Opt. 2002 Jul;7(3):457-63 [12175297.001]
  • [Cites] Arch Ophthalmol. 2003 May;121(5):695-706 [12742848.001]
  • [Cites] Hum Pathol. 2009 Aug;40(8):1057-69 [19552937.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):750-9 [17882019.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):564-72 [18234276.001]
  • [Cites] Ophthalmology. 2005 Oct;112(10):1734-46 [16140383.001]
  • (PMID = 21117602.001).
  • [ISSN] 1938-2375
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY008098; United States / NEI NIH HHS / EY / R01 EY013178; United States / NEI NIH HHS / EY / P30-EY08098; United States / NEI NIH HHS / EY / R01-EY13178
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS307169; NLM/ PMC3147151
  •  go-up   go-down


12. Radovanović D, Stevanović D, Pavlović I, Jasarović D, Mitrović N, Ilić I: [Gastrointerstinal stromal tumors of the stomach--case reports]. Med Pregl; 2008 Jul-Aug;61(7-8):409-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointerstinal stromal tumors of the stomach--case reports].
  • INTRODUCTION: Gastrointestinal stromal tumors are the most common mesenchimal tumors of the gastrointestinal tract.
  • The first patient was 59 years old male, with preoperatively diagnosed colonic cancer.
  • Intraoperatively besides the transverse colon cancer, we found intramural gastric tumor.
  • The immunohystochemical analysis of gastric tumor proves benign GIST.
  • The endoscopic ultrasound showed intramural tumor of the anterior gastric wall, with a visible blood vessel bleeding during endoscopy.
  • DISCUSSION: In the cases with inadequate preoperative diagnoses, the level of resection procedure is based on the size of tumor and the presence of necrosis and bleeding inside the tumor.
  • Tumors larger than 5 cm in diameter with signs of necrosis and bleeding are parameters of malignant nature of GIST, therefore demanding a radical surgical treatment.
  • CONCLUSION: The surgical resection is a treatment of choice for gastrointestinal stromal tumors.
  • [MeSH-major] Gastrointestinal Stromal Tumors. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097381.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


13. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One; 2010;5(10)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability.
  • Based on a consensus of the results obtained by two normalization algorithms, and two probe set sorting criteria, we identified 14 and 17 KEGG signaling and metabolic pathways that are significantly altered between normal and tumor samples and between benign and malignant tumors, respectively.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Oligonucleotide Array Sequence Analysis. Oncogenes. Signal Transduction

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3544-9 [11325815.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):395-401 [11687950.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Gut. 2003 Aug;52(8):1148-53 [12865273.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):323-31 [14960458.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1377-91 [14973550.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):335-51 [10448282.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):480-6 [15685558.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):517-24 [15706427.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] BMC Bioinformatics. 2005;6:80 [15799785.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):391-402 [15883783.001]
  • [Cites] Expert Rev Mol Diagn. 2006 May;6(3):465-80 [16706747.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1829-36 [16721809.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10):872-82 [16924468.001]
  • [Cites] World J Gastroenterol. 2006 Nov 21;12(43):6998-7006 [17109495.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):103-37 [17010523.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Cancer Detect Prev. 2007;31(4):282-95 [17936523.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1263-75 [18171984.001]
  • [Cites] Mol Cancer. 2007;6:79 [18081933.001]
  • [Cites] BMC Bioinformatics. 2008;9:140 [18318917.001]
  • [Cites] BMC Bioinformatics. 2008;9:164 [18366762.001]
  • [Cites] Surg Clin North Am. 2008 Aug;88(4):681-704, v [18672136.001]
  • [Cites] Dis Markers. 2008;25(1):1-16 [18776587.001]
  • [Cites] Nat Biotechnol. 2008 Sep;26(9):1003-10 [18711341.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2835-45 [18843029.001]
  • [Cites] World J Gastroenterol. 2008 Oct 14;14(38):5887-92 [18855989.001]
  • [Cites] Biotechniques. 2008 Nov;45(5):501-20 [19007336.001]
  • [Cites] Cell Oncol. 2009;31(1):19-29 [19096147.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):201-9 [19081199.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):165-75 [19328798.001]
  • [Cites] J Biomed Inform. 2009 Aug;42(4):605-11 [19535009.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Sep;9(6):623-30 [19732006.001]
  • [Cites] Br J Cancer. 2010 Feb 16;102(4):765-73 [20087348.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):41-56 [17210682.001]
  • [ErratumIn] PLoS One. 2010;5(12) doi: 10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca. Ostrowsk, Jerzy [corrected to Ostrowski, Jerzy]
  • (PMID = 20957034.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2948500
  •  go-up   go-down


14. Leinung S, Möbius C, Udelnow A, Hauss J, Würl P: Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience. Eur J Surg Oncol; 2007 May;33(4):508-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience.
  • RESULTS: We treated 597 patients with soft tissue tumors.
  • Open biopsy revealed soft tissue sarcoma in 318 cases, benign mesenchymal tumor in 124 cases and isolated metastases (ISTM) from carcinomas in 98 patients; other pathologies were found in 57 patients.
  • The primary carcinomas were lung cancer in 26 patients, breast cancer in 19 patients, renal carcinoma in 16 patients, carcinoma of the esophagus in 12 patients, colonic carcinoma in 5 patients, thyroid gland cancer in 6 patients, and in 14 patients carcinoma of unknown primary was diagnosed.
  • CONCLUSIONS: In our collective with soft tissue tumor, 50% of the patients had the diagnosis of soft tissue sarcoma, 20% presented with a metastasis of carcinoma and 20% had a benign tumor.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081724.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Saleh H, El-Fakharany M, Frankle M: Multiple synchronous granular cell tumors involving the colon, appendix and mesentery: a case report and review of the literature. J Gastrointestin Liver Dis; 2009 Dec;18(4):475-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple synchronous granular cell tumors involving the colon, appendix and mesentery: a case report and review of the literature.
  • A granular cell tumor (GCT) is typically a benign neural tumor of Schwann cell origin that occurs in the 4th to 6th decade of life usually as a solitary painless nodule in the dermis or subcutis.
  • Within the GI tract, it is most common in the esophagus followed by colon.
  • Colonic GCT is mostly found incidentally during colonoscopy or surgical resection as a solitary submucosal sessile nodule, although, some may cause rectal bleeding.
  • Full colonoscopy and CT-scan studies revealed multiple GCTs of the colon, appendix and the mesentery, raising the suspicion of malignant metastatic disease.
  • However, surgical resection of all the masses in an exploratory laporatomy proved them to be benign GCTs.
  • This case emphasizes the need to consider GCTs of the GI tract when multiple asymptomatic lesions are found incidentally in the colon before any aggressive surgical intervention is undertaken.
  • [MeSH-major] Appendiceal Neoplasms / diagnosis. Colonic Neoplasms / diagnosis. Granular Cell Tumor / diagnosis. Incidental Findings. Mesentery / pathology. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076822.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 22
  •  go-up   go-down


16. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T, Omata M: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology; 2009 Jan;136(1):206-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
  • The clinicopathologic (age, sex, and tumor site and grade) and molecular (KRAS gene mutation, as well as CTNNB1 and TP53 expression patterns) factors that could affect RASAL1 expression were examined.
  • RASAL1 expression levels were correlated with the presence of wild-type KRAS gene in CRC tumor samples (P= .0010), distal location (P= .0066), and abnormal expression of TP53 (P= .0208).
  • Reductions in RASAL1 expression were detected more frequently in advanced lesions than in small adenomas, suggesting that RASAL1 functions in the progression of benign colonic neoplasms.
  • [MeSH-major] Colorectal Neoplasms / etiology. Tumor Suppressor Proteins / physiology. ras GTPase-Activating Proteins / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Disease Progression. Female. Gene Silencing. Genes, ras. Humans. Male. Middle Aged. Signal Transduction


17. Shantha Kumara HM, Cabot JC, Hoffman A, Luchtefeld M, Kalady MF, Hyman N, Feingold D, Baxter R, Whelan RL: Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period. Surg Endosc; 2009 Apr;23(4):694-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period.
  • VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2.
  • The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Minimally Invasive Surgical Procedures / methods. Vascular Endothelial Growth Factor Receptor-1 / blood. Vascular Endothelial Growth Factor Receptor-2 / blood

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):44-50 [7615975.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] J Vasc Surg. 1998 Sep;28(3):535-40 [9737465.001]
  • [Cites] Am J Cardiol. 1999 Feb 1;83(3):337-9 [10072219.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):405-10 [17214745.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):490-8 [10667605.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):14-8 [11857378.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Sci STKE. 2001 Dec 11;2001(112):re21 [11741095.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):608-13 [16891801.001]
  • [Cites] Crit Care Med. 2008 Apr;36(4):1284-9 [18379256.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):617-23 [11274009.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3824-30 [10339489.001]
  • [Cites] Shock. 2008 Apr;29(4):452-7 [18598002.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Circ Res. 2001 Feb 2;88(2):167-74 [11157668.001]
  • [Cites] Clin Sci (Lond). 1997 May;92(5):453-4 [9176017.001]
  • [Cites] Surg Endosc. 2009 Feb;23(2):409-15 [18813991.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1931-4 [11929804.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):331-5 [12653578.001]
  • [Cites] Eur Respir J. 2001 Jul;18(1):100-6 [11510779.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Cancer. 2004 May 1;100(9):1884-91 [15112269.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • [Cites] Clin Exp Immunol. 2000 Jan;119(1):182-8 [10606981.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1375-9 [1402682.001]
  • (PMID = 19184203.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


18. Eriksen JR, Ibsen PH, Gyrtrup HJ: [Granular cell tumor of the colon--Abrikossoff's tumor]. Ugeskr Laeger; 2006 May 22;168(21):2080-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granular cell tumor of the colon--Abrikossoff's tumor].
  • [Transliterated title] Granularcelletumor i colon--Abrikossoffs tumor.
  • A 50-year-old woman had a right hemicoletomy due to a large sessile polyp in the ascending colon, inappropriate for polypectomy.
  • Histopathologic examination of the specimen showed a tubulovillous adenoma with moderate dysplasia and an adjacent 1 x 1 cm submucosal tumor classified as a benign GCT due to the appearance in the light microscope and immunohistochemical analysis.
  • To our knowledge, this is the first reported case of synchronic adenoma and GCT in the colon.
  • To date there is no evidence of any association or disposing factors between GCT in the colon and colonic adenomas or malignancy.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Granular Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768929.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


19. Chung WC, Kim HK, Yoo JY, Lee JR, Lee KM, Paik CN, Jang UI, Yang JM: Colonic lymphangiomatosis associated with anemia. World J Gastroenterol; 2008 Oct 7;14(37):5760-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic lymphangiomatosis associated with anemia.
  • Multiple colonic lymphangioma named as lymphangiomatosis is considered an extremely rare disease.
  • Although lymphangioma is a benign tumor and most colonic lymphangiomas do not cause symptoms and do not require treatment, resection of lymphangioma is necessary in the presence of symptoms such as abdominal pain, bleeding, intussusceptions.
  • We report a case of colonic lymphangiomatosis in a man who presented with abdominal discomfort and anemia, which was diagnosed and treated with endoscopic snare polypectomy.
  • [MeSH-major] Anemia / etiology. Colonic Neoplasms / complications. Lymphangioma / complications

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(2):146-8 [10936792.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6):781-4 [11115919.001]
  • [Cites] J Nippon Med Sch. 2001 Jun;68(3):262-5 [11404774.001]
  • [Cites] J Gastroenterol. 2002;37(5):381-6 [12051538.001]
  • [Cites] Surg Today. 2002;32(8):734-7 [12181728.001]
  • [Cites] J Gastroenterol. 2003;38(2):181-5 [12640534.001]
  • [Cites] Am J Dig Dis. 1975 Nov;20(11):1076-80 [1200000.001]
  • [Cites] Arch Surg. 1985 Nov;120(11):1266-9 [4051731.001]
  • [Cites] Radiology. 1994 Sep;192(3):697-702 [8058936.001]
  • [Cites] Gastrointest Endosc. 1995 Mar;41(3):252-4 [7789688.001]
  • [Cites] Gastrointest Endosc. 1997 Feb;45(2):204-6 [9041015.001]
  • [Cites] J Clin Gastroenterol. 1997 Apr;24(3):186-7 [9179742.001]
  • [Cites] J Clin Gastroenterol. 1997 Jul;25(1):383-6 [9412929.001]
  • [Cites] J Gastroenterol. 1999 Aug;34(4):520-4 [10452688.001]
  • [Cites] Dig Dis Sci. 2005 Sep;50(9):1747-53 [16133983.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Oct;16(5):530-3 [17004884.001]
  • (PMID = 18837097.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2748215
  •  go-up   go-down


20. John R, El-Rouby NM, Tomasetto C, Rio MC, Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol; 2007 07;22(7):743-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TFF3 during multistep colon carcinogenesis.
  • The pathogenesis of colon cancer is not well understood.
  • This common type of cancer is generally believed to occur in a multistep process which involves alterations of various tumor suppressor genes and oncogenes during the progression through benign lesions towards carcinoma.
  • TFF3 is a product of the colonic epithelium and has been implicated in colonic mucosal protection and also in the aggressiveness of colon cancer cells.
  • The aim of this study was to analyze the expression of TFF3 during propagation towards cancer development in the human colon.
  • Colonic tissues representing colitis, adenomatous polyposis, tubulovillous adenoma, and mucoid/adeno-carcinomas were processed for immunohistochemistry using an antibody specific for human TFF3.
  • The results were correlated with those of PCNA-labeling, quantified, and compared with those of control tissues obtained from the safe margin of macroscopically normal colonic mucosa of patients with colon cancer.
  • Colonic tissues with highly invasive cancer cells were characterized by statistically significant down-regulation of TFF3 expression.
  • The changes observed in expression of TFF3 showed an inverse correlation with cell proliferation and suggest that it might play a protective role against colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Adenoma, Villous / chemistry. Adenomatous Polyposis Coli / chemistry. Colitis / metabolism. Colonic Neoplasms / chemistry. Peptides / analysis
  • [MeSH-minor] Adult. Cell Proliferation. Cell Transformation, Neoplastic / chemistry. Colon / chemistry. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Trefoil Factor-3

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455148.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Peptides; 0 / Proliferating Cell Nuclear Antigen; 0 / TFF3 protein, human; 0 / Trefoil Factor-3
  •  go-up   go-down


21. Ivanova A, Iarŭmov N, Toshev S, Adzharov D, Krŭstev Z, Angelov K, Sokolov M, Gribnev P: [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma]. Khirurgiia (Sofiia); 2007;(6):5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the level of tumor marker pyruvate kinase dimer (M2-PK) in the feces of patients with colorectal cancer and benign polyps, as well as in individuals with chronic inflammatory bowel diseases.
  • The establishing of elevated values in patients with chronic inflammatory bowel diseases decreases the specificity of M2-PK as a tumor marker.
  • [MeSH-minor] Colonic Polyps / diagnosis. Colonic Polyps / enzymology. Early Diagnosis. Enzyme-Linked Immunosorbent Assay. Feces / chemistry. Female. Humans. Inflammatory Bowel Diseases / diagnosis. Inflammatory Bowel Diseases / enzymology. Male. Middle Aged. Pilot Projects. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622373.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] EC 2.7.1.40 / Pyruvate Kinase
  •  go-up   go-down


22. Ples R, Lazure T, Dimet S, Lascar G, Sales JP, Moulin G, Ladouch-Badre A, Guettier C: [Epithelioid schwannoma of the colon. Report of two cases]. Ann Pathol; 2007 Jun;27(3):243-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid schwannoma of the colon. Report of two cases].
  • [Transliterated title] Schwannome épithélioïde colique: étude anatomo-clinique de deux cas.
  • Schwannomas of the colon are rare tumors.
  • Most of them are spindle cell tumors.
  • The masses were located in the sigmoid and the right colon.
  • One of them had a cuff of benign lymphoid hyperplasia.
  • Immunohistochemical study showed positive staining of the tumor cells for S100 protein and some of them for glial fibrillary acidic protein.
  • Some CD34-positive fibroblast-like cells were identified in the two tumors.
  • Epithelioid schwannoma of the colon is a benign tumor of uncertain histogenesis which may be confused with more aggressive neoplasms.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasms, Glandular and Epithelial / pathology. Neurilemmoma / pathology. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978700.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


23. Bianchi PP, Ceriani C, Montorsi M: [Laparoscopic surgery of colon cancer. State of art and literature review]. Ann Ital Chir; 2006 Jul-Aug;77(4):289-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery of colon cancer. State of art and literature review].
  • [Transliterated title] La chirurgia laparoscopica nel tumore del colon. Stato dell'arte e revisione della letteratura.
  • Despite reduced morbidity and improved convalescence after laparoscopic surgery for benign disorders, surgeons have been sceptical about similar advantages of laparoscopic colectomy for cancer.
  • The safety of the procedure has been questioned because of early reports of port-site metastases and there has been uncertainty about whether minimally invasive surgery for colonic malignancies would achieve adequate oncologic resection.
  • Open surgical resection of the primary tumor, until just recently, has been widely considered the most effective treatment of colon cancer.
  • The adherence to the principles of complete abdominal exploration, high ligation of mesenteric vessels, lymphnodal clearance and adequate bowel resection margins is essential.
  • Several randomized trials were initiated in the early 1990s to compare the short- and long-term outcomes of patients undergoing minimally invasive and conventional open surgery for colon cancer.
  • [MeSH-major] Colonic Neoplasms / surgery. Laparoscopy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139955.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 21
  •  go-up   go-down


24. Lazaraki G, Tragiannidis D, Xirou P, Nakos A, Pilpilidis I, Katsos I: Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report. Cases J; 2009;2:6462
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of giant lipoma mimicking colonic neoplasm initially presenting with massive haemorrhage: a case report.
  • Lipomas of the colon are benign tumors that rarely occur.
  • They are usually asymptomatic but occasionally they present with clinical manifestations depending on tumor size, localization and complications, which often lead to diagnostic difficulty.
  • During colonoscopy a giant polyp of over 50 mm in its bigger diameter, with a thick stalk of 2 cm, located in the transverse colon, was revealed.
  • In this report discussion over endoscopic resection of colonic lipomas mimicking neoplasms is also performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Nov;30(11):888-93 [3677966.001]
  • [Cites] Dig Dis Sci. 2008 Oct;53(10):2826-7 [18270829.001]
  • [Cites] Dis Colon Rectum. 1972 Nov-Dec;15(6):441-4 [4645612.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jul;5(3):713-21 [8829328.001]
  • [Cites] Surg Endosc. 1998 Jan;12(1):42-5 [9419301.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2143-4 [10950091.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1295-7 [11316189.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1944-6 [11419863.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):929-31 [12024158.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):756-9 [15855988.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):988-90 [16301055.001]
  • [Cites] Indian J Gastroenterol. 2007 Sep-Oct;26(5):254-5 [18227586.001]
  • [Cites] Eur J Surg. 1991 Jan;157(1):51-5 [1675882.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):532-3 [2152245.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):435-8 [2227312.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):509-11 [2227328.001]
  • [Cites] Am Surg. 1985 Aug;51(8):449-54 [4026070.001]
  • (PMID = 20181161.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827102
  •  go-up   go-down


25. Galamb O, Sipos F, Solymosi N, Spisák S, Krenács T, Tóth K, Tulassay Z, Molnár B: Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2835-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results.
  • PURPOSE: Gene expression profile (GEP)-based classification of colonic diseases is a new method for diagnostic purposes.
  • EXPERIMENTAL DESIGN: Total RNA was extracted, amplified, and biotinylated from frozen colonic biopsies of patients with colorectal cancer (n=22), adenoma (n=20), hyperplastic polyp (n=11), inflammatory bowel disease (n=21), and healthy normal controls (n=11), as well as peripheral blood samples of 19 colorectal cancer and 11 healthy patients.
  • [MeSH-minor] Adenoma / blood. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Case-Control Studies. Chi-Square Distribution. Colonic Polyps / blood. Colonic Polyps / genetics. Colonic Polyps / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Inflammatory Bowel Diseases / blood. Inflammatory Bowel Diseases / pathology. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843029.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


26. Ghossain MA, Chucrallah A, Kanso H, Aoun NJ, Abboud J: Multilocular adenomatoid tumor of the ovary: ultrasonographic findings. J Clin Ultrasound; 2005 Jun;33(5):233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilocular adenomatoid tumor of the ovary: ultrasonographic findings.
  • We report the sonographic findings of a rare benign ovarian tumor in a 69-year-old woman.
  • Surgery revealed an adenomatoid tumor.
  • Adenomatoid tumors are benign lesions of mesothelial origin, usually solid in nature and rarely located in the ovaries. (c) 2005 Wiley Periodicals, Inc.
  • [MeSH-major] Adenomatoid Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Female. Humans. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc. J Clin Ultrasound 33:233-236, 2005.
  • (PMID = 16047378.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Chuang D, Paddison JS, Booth RJ, Hill AG: Differential production of cytokines following colorectal surgery. ANZ J Surg; 2006 Sep;76(9):821-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These complications are more common after rectal surgery than after colon surgery.
  • Hence we suggested that differential secretion of these may contribute to the differences in complications between colon and rectal surgeries.
  • METHODS: Patients undergoing either elective rectal excision or colectomy for benign or malignant disease were recruited into the study.
  • The drain fluid was assayed for interleukin (IL)-1beta, tumour necrosis factor-alpha, IL-6, IL-8, IL-10 and IL-13 using multiplexed biomarker immunoassays.
  • CONCLUSION: This study has shown that the concentration of IL-8 in the region of the anastomosis of patients who have undergone rectal surgery is much higher than those who have undergone colonic surgery.
  • [MeSH-major] Colon / secretion. Colon / surgery. Interleukins / secretion. Rectum / secretion. Rectum / surgery. Tumor Necrosis Factor-alpha / secretion

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922906.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Interleukins; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


28. Bosserhoff AK, Grussendorf-Conen EI, Rübben A, Rudnik-Schöneborn S, Zerres K, Buettner R, Merkelbach-Bruse S: Multiple colon carcinomas in a patient with Cowden syndrome. Int J Mol Med; 2006 Oct;18(4):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple colon carcinomas in a patient with Cowden syndrome.
  • Cowden syndrome is a non-adenomatous gastrointestinal polyposis syndrome with inactivation of PTEN, a dual-phosphatase tumor suppressor gene.
  • Patients with loss of wildtype PTEN expression from one allele carry an increased risk of malignant breast, thyroid and brain tumors.
  • In this study, we describe a kindred with Cowden syndrome and identify a heterozygous germline mutation causing truncation of the PTEN tumor suppressor.
  • The index patient was a 56 year-old woman having multiple facial papules, acral keratosis, oral papillomatosis, multiple benign breast and thyroid tumors and gastrointestinal polyposis.
  • [MeSH-major] Colonic Neoplasms / pathology. Hamartoma Syndrome, Multiple / pathology

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964417.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / RNA, Messenger; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


29. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem; 2010 Mar;58(3):277-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synthesis and degradation of the secosteroid occurs not only in the kidney but also in normal tissue or malignant extrarenal tissues such as the colon.
  • Because 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24A1) is considered to be the main enzyme determining the biological half-life of 1,25-D(3), we have examined expression of the CYP24A1 mRNA (by real-time RT-PCR) and protein (by immunohistochemistry) in normal human colon mucosa, colorectal adenomas, and adenocarcinomas in 111 patients.
  • Although 76% of the normal and benign colonic tissue was either completely devoid of or expressed very low levels of CYP24A1, in the majority of the adenocarcinomas (69%), the enzyme was present at high concentrations.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / enzymology. Steroid Hydroxylases / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Colon / enzymology. Female. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Ki-67 Antigen / biosynthesis. Male. Middle Aged. RNA, Messenger / biosynthesis. Receptors, Calcitriol / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Vitamin D3 24-Hydroxylase

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 2000 May;127(5):717-22 [10788778.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1581-9 [15905206.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6158-65 [11012668.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):847-52 [11075874.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):888-94 [11158062.001]
  • [Cites] Steroids. 2001 Mar-May;66(3-5):409-22 [11179750.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1043-51 [11309356.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 27;285(4):1012-7 [11467853.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):257-62 [11934953.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1583-8 [12352462.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):31-41 [16145679.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94 [16236494.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40 [16180015.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1424-33 [16247453.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):415-24 [16556015.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 [16886679.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1819-28 [16708384.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1119-26 [17182978.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3131-8 [18089708.001]
  • [Cites] Curr Med Res Opin. 2008 Jan;24(1):139-49 [18034918.001]
  • [Cites] Mol Aspects Med. 2008 Dec;29(6):388-96 [18755215.001]
  • [Cites] Recent Results Cancer Res. 2003;164:239-46 [12899526.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):38084-93 [12867411.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):236-41 [14760115.001]
  • [Cites] J Cutan Pathol. 2004 Mar;31(3):224-31 [14984574.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):693-702 [15077124.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):985-9 [15208365.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Steroids. 1990 Sep;55(9):395-8 [2281516.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):24673-8 [7929139.001]
  • [Cites] J Invest Dermatol. 1997 Apr;108(4):513-8 [9077483.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 May;62(1):21-8 [9366495.001]
  • [Cites] Endocrinology. 1999 May;140(5):2071-6 [10218956.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):82-90 [10337990.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20604-11 [15788398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7 [16103450.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):977-84 [10891358.001]
  • (PMID = 19901270.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2825493
  •  go-up   go-down


30. Jiang B, Ren T, Dong B, Qu L, Jin G, Li J, Qu H, Meng L, Liu C, Wu J, Shou C: Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol; 2010 Sep;177(3):1095-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients.
  • Tumor-associated antigens, which induce the generation of autoantibodies, are useful as cancer biomarkers in early detection and prognostic prediction of cancer.
  • To isolate a novel cancer marker, we used serum antibodies from colon cancer patients to screen a phage display peptide library.
  • A positive peptide 249C (VPLYSNTLRYGF) that could specifically react with serum from colon cancer patients was isolated, and the corresponding antigen-human arrest defective 1 (ARD1A), which shares an identical LYSNTL motif with 249C, was identified.
  • Using ELISA and immunohistochemistry, we found anti-ARD1A antibody levels in serum from patients with colon cancer were significantly higher than those in healthy volunteers (P < 0.001), and ARD1A expression was detected in 84.1% (227/270) of colon cancer tissues compared with 22.7% (55/242) of matched noncancerous tissues (P < 0.001) and 4.8% (2/42) of benign lesions (P < 0.001).
  • These results indicate that ARD1A is a novel tumor-associated antigen and a potential prognostic factor for colon cancer.
  • [MeSH-major] Acetyltransferases / blood. Antigens, Neoplasm / blood. Autoantibodies / blood. Colonic Neoplasms / blood. Colonic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biomarkers, Tumor / isolation & purification. Blotting, Western. Cell Line, Tumor. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Epitopes / isolation & purification. Humans. Kaplan-Meier Estimate. Middle Aged. N-Terminal Acetyltransferase A. N-Terminal Acetyltransferase E. Prognosis. Proportional Hazards Models

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31132-40 [15994306.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17749-57 [15755738.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1131-6 [16279846.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4350-60 [16518407.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10677-82 [17108104.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):619-26 [17998402.001]
  • [Cites] Cancer Lett. 2008 Jun 8;264(1):83-92 [18325661.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1296-310 [18471507.001]
  • [Cites] Histopathology. 2009 Feb;54(3):309-18 [19236507.001]
  • [Cites] Biochem J. 2009 Apr 1;419(1):133-9 [18973474.001]
  • [Cites] Oncol Rep. 2009 Apr;21(4):909-15 [19287988.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15209-14 [11742062.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):636-43 [12079511.001]
  • [Cites] Cell. 2002 Nov 27;111(5):709-20 [12464182.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):57-63 [12496764.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2572-82 [15352232.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):16-20 [7505195.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4656-62 [15536075.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):433-43 [15496142.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • (PMID = 20639454.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  • [Other-IDs] NLM/ PMC2928944
  •  go-up   go-down


31. Mnif L, Amouri A, Masmoudi MA, Mezghanni A, Gouiaa N, Boudawara T, Tahri N: Giant lipoma of the transverse colon: a case report and review of the literature. Tunis Med; 2009 Jun;87(6):398-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant lipoma of the transverse colon: a case report and review of the literature.
  • BACKGROUND: Colonic lipomas are benign adipose tumors which are usually submucosal.
  • AIM: We report a case of symptomatic giant colonic lipoma OBSERVATION: A 67-year old woman was admitted to hospital with persistent abdominal pain, for which a barium enema showed a large polypoid mass occluding the lumen of the transverse colon.
  • Colonoscopy revealed a tumor narrowing the bowel lumen of about 5 cm in diameter with a sessile appearance and ulcerated overlying mucosa.
  • The possibility of colonic malignancy could not be precluded and an operative resection was performed.
  • Pathological examination revealed a colonic lipoma.
  • CONCLUSION: Awareness of the possibility of colonic lipomas is important for clinicians in terms of evaluation of therapeutic regimen.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Lipoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927786.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Tunisia
  • [Number-of-references] 26
  •  go-up   go-down


32. Cervantes-Solís C, Jiménez-González A, Zamora-Nava LE, Torre-Delgadillo A: [Thickening of the colon and terminal ileum documented with computer tomography and its correlation with colonoscopic findings at a third-level hospital]. Rev Gastroenterol Mex; 2010;75(2):158-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thickening of the colon and terminal ileum documented with computer tomography and its correlation with colonoscopic findings at a third-level hospital].
  • [Transliterated title] Engrosamiento colónico y de íleon terminal documentado por tomografía computarizada y su correlación con hallazgos colonoscópicos en un hospital de tercer nivel.
  • BACKGROUND: Tomographic finding of thickening of colon and terminal ileum and its correlation with colonoscopic findings has been poorly studied.
  • Various radiographic patterns of intestinal thickening suggestive of benign disease have been described, but they cannot completely rule out malignancy.
  • OBJECTIVE: To determine if a relationship exists between colonic wall or terminal ileum thickening documented by computed tomography with abnormal colonoscopic findings and colon cancer.
  • METHODS: Retrospective study of radiology database of a tertiary hospital identifying patients with report of thickening of terminal ileum or colon and have colonoscopy performed.
  • The main site of colonic thickening on CT was sigmoid in 8 (33.3%) cases.
  • The most common colonoscopic finding was colorectal tumor probably malignant in 7 (29.2%) patients, but adenocarcinoma was reported in 8 (33.3%) patients.
  • There was a statistically significant relationship between colonic thickening and colorectal cancer (p < 0.001) but no statistically significant association was found between thickening and sigmoid colon cancer.
  • CONCLUSIONS: The finding of thickening of colon documented by computed tomography is significantly associated with the presence of colorectal carcinoma.
  • [MeSH-major] Colon / pathology. Colon / radiography. Colonic Neoplasms / diagnosis. Colonoscopy. Ileum / pathology. Ileum / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20615783.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


33. Scherer K, Johnston J, Panda M: Dural based mass: malignant or benign. J Radiol Case Rep; 2009;3(11):1-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural based mass: malignant or benign.
  • In March 2007, a 68 year old female was diagnosed with colonic adenocarcinoma metastatic to the lungs and a frontoparietal parafalcine lesion suspected to be a meningioma was also noted.
  • Pathology indicated metastatic adenocarcinoma with colonic primary without evidence of meningioma.
  • Dural metastatic tumors mimicking meningiomas is an uncommon phenomenon, particularly when the primary location is the colon.
  • This paper additionally discusses the differentiation of benign dural based tumors like meningiomas from malignant findings.
  • Multiple adjunct studies can differentiate meningiomas from metastatic tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Dec;33(12):1211-26 [12514791.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jun;44(6):317-20 [15253548.001]
  • [Cites] Acta Cytol. 1981 Sep-Oct;25(5):461-79 [7025541.001]
  • [Cites] Acta Cytol. 1981 Nov-Dec;25(6):599-610 [6947665.001]
  • [Cites] Neurosurgery. 1986 Nov;19(5):820-3 [3785633.001]
  • [Cites] J Neurosurg Sci. 1987 Jan-Mar;31(1):33-6 [3625287.001]
  • [Cites] Neuroradiology. 1993;35(4):272-3 [8492892.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Feb;34(2):108-10 [7514757.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):345-67 [8823768.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):241-5 [12480230.001]
  • [Cites] Otol Neurotol. 2002 Nov;23(6):975-9 [12438865.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):193-9 [12187955.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):880-7 [11419971.001]
  • [Cites] Australas Radiol. 2005 Dec;49(6):497-500 [16351616.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):135-7 [9213059.001]
  • [Cites] Neurologist. 2006 Jan;12(1):48-52 [16547447.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):57-61 [16215816.001]
  • [Cites] Neurochirurgie. 1999 May;45(2):160-3 [10448659.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):552-8 [9761048.001]
  • (PMID = 22470624.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303278
  • [Keywords] NOTNLM ; Dural based mass / meningioma / metastatic dural based lesions
  •  go-up   go-down


34. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • We have used quantitative real-time PCR to investigate the expression of SASH1 in tissue samples from 113 patients with colon carcinoma, and compared the expression with 15 normal colon tissue samples.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • Expression levels of SASH1 were strongly and significantly reduced in colon cancer of UICC stage II, III, and IV, as well as in liver metastases.
  • Overall, 48 out of 113 primary colon tumours showed SASH1 expression that was at least 10-fold lower than the levels found in normal colon tissue.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


35. Steff M, Bourillon A, Frebourg T, Balderi X, Descamps V, Joly P, Piette F, Crestani B, Grandchamp B, Soufir N: [Intra- and interfamilial phenotype variation in Birt-Hogg-Dubé syndrome: Consequences for therapy]. Ann Dermatol Venereol; 2010 Mar;137(3):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Variation phénotypique intra- et interfamiliale dans le syndrome de Birt-Hogg-Dubé : conséquences sur la prise en charge.
  • BACKGROUND: Birt-Hogg-Dubé syndrome (BHDS) is an autosomal-dominantly inherited genodermatosis that predisposes to the development of benign hair follicle tumours, lung cysts, kidney tumours, and possibly colonic cancers, due to mutations in the FLCN gene.
  • The first proband showed fibrofolliculomas (FF), a history of pneumothorax and colonic adenoma.
  • [MeSH-major] Frameshift Mutation. Hair Follicle / pathology. Proto-Oncogene Proteins / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Colonic Neoplasms / genetics. Emphysema / genetics. Female. Hair Diseases / genetics. Humans. Male. Middle Aged. Pedigree. Phenotype. Pneumothorax / genetics. Sequence Analysis, Protein

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Masson SAS.
  • (PMID = 20227563.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


36. Doll D, Keller L, Maak M, Boulesteix AL, Siewert JR, Holzmann B, Janssen KP: Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Colorectal Dis; 2010 May;25(5):573-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival.
  • However, their contribution to tumor formation remains incompletely understood.
  • The aim of the present study was to investigate the regulation of their expression in colon cancer cells and to test the hypothesis that altered CXC-chemokine expression is related to critical clinical parameters, such as survival or metastasis formation.
  • MATERIALS AND METHODS: Expression levels of interleukin-8 (CXCL-8) and growth-related oncogenes 2 and 3 (GRO-2/CXCL-2 and GRO-3/CXCL-3) were quantified using qRT-PCR in 97 patients with completely resected colon carcinoma and correlated with clinical parameters.
  • Moreover, 16 samples of normal mucosa, nine samples of benign adenoma, and 11 samples of liver metastasis were analyzed.
  • Next, the regulation of chemokine expression in response to various stimuli was tested in colon cancer cell lines (HT29, HCT116, CaCO2).
  • RESULTS: Expression of GRO-2, GRO-3, and IL-8 was significantly increased in colon cancer as compared to normal colon tissue.
  • Expression of GRO-2 and GRO-3 was already enhanced in premalignant adenomas, and GRO-3 was significantly down-regulated in liver metastasis as compared to the primary tumor.
  • Finally, all chemokines were strongly induced by IL-1alpha in the colon cancer cell lines tested, indicating a potential link to inflammatory processes.
  • CONCLUSION: In accordance with earlier findings, we report here a significantly increased expression of GRO-2, GRO-3, and IL-8 in colon carcinoma as compared to normal tissue.
  • [MeSH-major] Chemokine CXCL2 / genetics. Chemokines, CXC / genetics. Colonic Neoplasms / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Interleukin-8 / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 2002 Nov;72(5):847-55 [12429706.001]
  • [Cites] ILAR J. 1999 Sep;40(4):175-182 [11406696.001]
  • [Cites] J Gastroenterol. 1994 Aug;29(4):423-9 [7951851.001]
  • [Cites] J Lab Clin Med. 1998 Aug;132(2):97-103 [9708570.001]
  • [Cites] World J Gastroenterol. 2007 Oct 7;13(37):4996-5002 [17854143.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3581-4 [16101183.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27348-57 [7592998.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3298-304 [11595728.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):437-43 [15734970.001]
  • [Cites] Melanoma Res. 1999 Aug;9(4):383-7 [10504057.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):397-407 [1497091.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1910-3 [14696431.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):391-402 [15883783.001]
  • [Cites] J Cell Biochem. 1988 Feb;36(2):185-98 [3356754.001]
  • [Cites] Cancer Immunol Immunother. 1994 Mar;38(3):167-70 [8124684.001]
  • [Cites] Biochemistry. 1997 Mar 4;36(9):2716-23 [9054580.001]
  • [Cites] Melanoma Res. 1995 Jun;5(3):179-81 [7640519.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):783-9 [10213213.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1214-23 [9322516.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):2069-77 [7500052.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):492-504 [12145803.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3711-21 [10589791.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2290-9 [10786697.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):317-22 [15958053.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20431-7 [11923281.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5951-9 [17062666.001]
  • [Cites] Exp Dermatol. 1998 Dec;7(6):335-41 [9858136.001]
  • [Cites] Surg Oncol. 1992 Aug;1(4):323-9 [1341267.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):1039-52 [18045955.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2735-40 [10914718.001]
  • [Cites] J Leukoc Biol. 1997 Nov;62(5):554-62 [9365108.001]
  • [Cites] Cytokine. 2000 Jan;12(1):78-85 [10623446.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2747-56 [17363596.001]
  • [Cites] Mol Med. 2001 Aug;7(8):523-34 [11591888.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):226-44 [18579287.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):481-95 [15563311.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1970-6 [15545974.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5346-55 [17000667.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12085-93 [12556523.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] Cytokines. 1992;4:96-116 [1335322.001]
  • (PMID = 20162422.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CXCL2 protein, human; 0 / CXCL3 protein, human; 0 / Chemokine CXCL2; 0 / Chemokines, CXC; 0 / Interleukin-8
  •  go-up   go-down


37. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn; 2005 Aug;7(3):413-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and malignant tumors represent heterogenous tissue containing tumor cells and non-neoplastic mesenchymal and inflammatory cells.
  • In addition, Pyrosequencing proved superior to dideoxy sequencing in the detection of KRAS mutations from DNA mixtures of paraffin-embedded colon cancer and normal tissue as well as from paraffin-embedded pancreatic cancers.
  • It is particularly useful for tumors containing abundant non-neoplastic cells.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Mar;8(3):243-52 [11306349.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):428-35 [11861435.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):185-90 [12411585.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2164-70 [12446472.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4072-9 [12481262.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):243-9 [14573784.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):147-64 [14764940.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e53 [15037663.001]
  • [Cites] Hum Mutat. 2004 May;23(5):406-12 [15108270.001]
  • [Cites] Hum Mutat. 2004 May;23(5):437-41 [15108274.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:250-6 [15251969.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):236-42 [15269301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Biotechniques. 1994 May;16(5):938-43 [8068351.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1082-4 [7876379.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1382-90 [8787693.001]
  • [Cites] Diagn Mol Pathol. 1996 Dec;5(4):260-4 [8955617.001]
  • [Cites] Anal Biochem. 1997 May 1;247(2):394-403 [9177704.001]
  • [Cites] J Immunol Methods. 1997 Aug 7;206(1-2):11-9 [9328563.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):373-9 [9708798.001]
  • [Cites] Curr Opin Biotechnol. 1998 Dec;9(6):602-8 [9889145.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Biotechniques. 2000 Jan;28(1):140-4, 146-7 [10649785.001]
  • [Cites] Gene. 2000 Aug 8;253(2):249-57 [10940563.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Genome Res. 2001 Jan;11(1):3-11 [11156611.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):105-10 [15681481.001]
  • (PMID = 16049314.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P01-9467802; United States / PHS HHS / / P01-9483703; United States / PHS HHS / / R01-9485602
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867544
  •  go-up   go-down


38. Tralhão JG, Hoti E, Serôdio M, Laranjeiro P, Paiva A, Abrantes AM, Pais ML, Botelho MF, Castro Sousa F: Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer. Eur J Surg Oncol; 2010 Feb;36(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer.
  • INTRODUCTION: Although there is general correlation between the TNM stage of colorectal cancer (CRC) and its prognosis, there is often significant variability of tumor behaviour and individual patient outcome, which is unaccounted for by pathologic factors alone.
  • Our aim was to estimate perioperative tumor cell dissemination in patients with primary or CRC liver metastases as a possible factor influencing the outcome.
  • Eighteen patients had histologically proven CRC (50% rectal, 44% colonic, 6% colonic and rectal).
  • The remaining six patients who underwent colon or liver resection for benign conditions, acted as the control group.
  • Blood samples were taken before the surgical incision (T0), immediately after tumor resection (T1) and at the end of the surgical intervention (T2).
  • CONCLUSIONS: This study demonstrates no differences in the detected circulating numbers of tumor cells at different stages of surgical intervention.


39. Agaimy A, Stoehr R, Vieth M, Hartmann A: Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations. Am J Surg Pathol; 2010 Nov;34(11):1663-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations.
  • Colorectal fibroblastic polyp and intramucosal perineurioma are 2 synonyms for a recently described benign mucosal lesion with a predilection for the rectosigmoid colon.
  • All lesions represented asymptomatic solitary polyps (mean size 3.5 mm) localized predominantly in the rectosigmoid colon (81%).
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Epithelial Cells / pathology. Fibroblasts / pathology. Intestinal Mucosa / pathology. Mutation. Nerve Sheath Neoplasms / pathology. Proto-Oncogene Proteins B-raf / genetics. Stromal Cells / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962618.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


40. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell; 2008 May;13(5):407-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.
  • The Drosophila transcription factor Prospero functions as a tumor suppressor, and it has been suggested that the human counterpart of Prospero, PROX1, acts similarly in human cancers.
  • However, we show here that PROX1 promotes dysplasia in colonic adenomas and colorectal cancer progression.
  • PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
  • Furthermore, in intestinal tumors PROX1 is a direct and dose-dependent target of the beta-catenin/TCF signaling pathway, responsible for the neoplastic transformation.
  • Our data underscore the complexity of cancer pathogenesis and implicate PROX1 in malignant tumor progression through the regulation of cell polarity and adhesion.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Homeodomain Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Cell Line, Tumor. Colorectal Neoplasms / genetics. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Phenotype. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455124.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 09-0791; United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


41. Ozkol V, Alper E, Aydin N, Ozkol HF, Topal NB, Akpinar AT: The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography. Nucl Med Commun; 2010 Feb;31(2):128-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nineteen of these 36 malignant or premalignant lesions were synchronous carcinomas, 14 lesions were unusual or unexpected malignant spread of known malignancy and three lesions were premalignant colonic adenomas.
  • Thirty-three of 74 incidental PET lesions were of benign origin (1.4% of 2370 patients and 44% of 74 PET foci).
  • CONCLUSION: The detection of incidental 18F-FDG-PET foci on PET/CT may reflect unexpected malignant lesions related to unusual malignant spread of primary malignancy or synchronous tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858768.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


42. Cosme A, Tejada A, Bujanda L, Vaquero M, Elorza JL, Ojeda E, Goikoetxea U: Littoral-cell angioma of the spleen: a case report. World J Gastroenterol; 2007 Dec 28;13(48):6603-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Littoral-cell angioma (LCA) is a primary splenic vascular tumor that arises from the normal littoral cells lining the sinus channels of the splenic red pulp.
  • A 76-year-old man with a 2-wk history of weight loss, abdominal pain and changes in bowel habits was admitted to our hospital.
  • Our case was associated with a serrated colonic adenoma.
  • LCA is a benign vascular tumor of the spleen that needs to be included in the differential diagnosis of multiple splenic nodules.

  • Genetic Alliance. consumer health - Angioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18161935.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers; 0 / CD68 antigen, human
  • [Other-IDs] NLM/ PMC4611304
  •  go-up   go-down


43. Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N: Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol; 2008 May;38(5):347-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, LN sites were divided into proximal and distant according to their distance from the primary tumor.
  • RESULTS: The mean SUV of the malignant LNs was significantly higher than that of the benign LNs.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonic Neoplasms / pathology. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Preoperative Care. ROC Curve. Radiopharmaceuticals. Rectal Neoplasms / pathology. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18424814.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Mouton WG, Kienle Y, Muggli B, Naef M, Wagner HE: Tumors associated with superficial thrombophlebitis. Vasa; 2009 May;38(2):167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors associated with superficial thrombophlebitis.
  • BACKGROUND: To assess the incidence of malignant tumors in patients with thrombophlebitis of the leg with regard to potential early tumor detection.
  • RESULTS: There were 18 patients (12.9%) suffering from thrombophlebitis in association with a malignant tumor: breast cancer in seven patients, colon carcinoma and haematologic cancer in four, skin cancer in three patients and one case each of oesophageal, prostatic, kidney and neck cancer .
  • Superficial thrombophlebitis may have been associated in four cases (2.9%) with a benign tumor.
  • CONCLUSIONS: Breast, colonic, haematological and skin cancer were mainly associated with superficial thrombophlebitis in our patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588305.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


45. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • The incidence of malignant colonic intussusception (63%) was significantly higher than that of enteric intussusception (20%), P = 0.001.
  • Primary colon adenocarcinoma (8 of 10 patients, 80%) and malignant lymphoma (2 of 10 patients, 20%) were the two most common underlying malignant lesions in the colon.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Mandal S, Kawatra V, Dhingra KK, Gupta P, Khurana N: Lipomatous Polyp Presenting With Intestinal Intussusception in Adults: Report of Four Cases. Gastroenterology Res; 2010 Oct;3(5):229-231
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipoma accounts for 4% of all benign tumors of the gut.
  • Though these lesions are benign, it continues to present difficulties in the preoperative differentiation between malignant and benign colonic neoplasm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27957003.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Adults / Intestine / Intussusception / Lipomatous polyp
  •  go-up   go-down


47. Sidani SM, Tawil AN, Sidani MS: Extraction of a large self-amputated colonic lipoma: A case report. Int J Surg; 2008 Oct;6(5):409-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraction of a large self-amputated colonic lipoma: A case report.
  • Despite being the most common benign tumor of nonepithelial origin in the colon, colonic lipomas are nonetheless considered a rare occurrence.
  • The minority of patients presenting with symptomatic colonic lipoma are generally treated with resection.
  • We report a case of a symptomatic patient who, on presentation, was found to have a partially obstructing, self-amputated colonic mass on colonoscopy, requiring endoscopic fragmentation to extrude what was later histologically diagnosed to be a lipoma.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonoscopes. Colonoscopy / methods. Lipoma / pathology. Lipoma / surgery
  • [MeSH-minor] Barium Sulfate. Colectomy / methods. Enema / methods. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947813.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


48. Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R: The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR. Int J Colorectal Dis; 2009 Mar;24(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR.
  • PURPOSE: The presence of regional lymph node metastases is one of the most important prognostic factors in colon cancer.
  • METHODS: In the present study, we have evaluated the detection of colon cancer lymph node metastases by real-time RT-PCR quantitation of the epithelial-specific cytokeratin 20 (CK20) and mucin 2 (MUC2) mRNAs.
  • RESULTS: Both assays were able to detect dilutions of tumor cells down to one tumor cell in 10(6) normal lymphocytes.
  • CK20 and MUC2 mRNA were quantitated in 52 normal lymph nodes from 12 patients undergoing surgery for benign bowel diseases and in 144 primary colon tumors.
  • The median tumor level of both markers were more than 10(4)-fold higher than the highest level in normal lymph nodes, indicating that the markers had a potential for metastasis detection in a clinical context.
  • CONCLUSIONS: Thus, CK20 and MUC2 quantitation by real-time RT-PCR seems to be a promising, sensitive tool to detect metastases in regional lymph nodes from colon cancer patients.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Keratin-20 / genetics. Lymph Nodes / pathology. Mucin-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Lymphocytes / metabolism. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2006 Sep 15;356(2):182-93 [16899212.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1070-80 [17206482.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):87-94 [13680284.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1304-12 [17460811.001]
  • [Cites] Cancer Detect Prev. 2000;24(1):72-9 [10757125.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):412-7 [14648708.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1386-92 [17009147.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1049-55 [11844829.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):101-10 [15185350.001]
  • [Cites] Nat Biotechnol. 2001 Nov;19(11):1011-2 [11689839.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):520-3 [16510433.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):617-28 [14520701.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):218-25 [16755296.001]
  • [Cites] J Mol Diagn. 2007 Nov;9(5):563-71 [17916603.001]
  • (PMID = 19119477.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Mucin-2; 0 / RNA, Messenger
  •  go-up   go-down


49. Oldenburg A, Albrecht T: [Baseline and contrast-enhanced ultrasound of the liver in tumor patients]. Ultraschall Med; 2008 Oct;29(5):488-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Baseline and contrast-enhanced ultrasound of the liver in tumor patients].
  • Conventional sonography is the most commonly used modality for liver imaging in tumor patients.
  • The majority of liver metastases are hypoechoic and well defined in baseline ultrasound (US), while detection of isoechoic or small liver metastases <1 cm is difficult and the differentiation of liver metastases from benign liver lesions and other malignant liver tumors can be impossible with baseline US.
  • Furthermore, the typical enhancement patterns of the different benign and malignant liver lesions allow reliable characterization and differentiation from liver metastases in the majority of cases.
  • This paper provides information about the advantages and expedient application of contrast-enhanced ultrasound (CEUS) in tumor patients.
  • [MeSH-major] Contrast Media. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Neoplasm Metastasis / ultrasonography
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Colonic Neoplasms / pathology. Colonic Neoplasms / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neovascularization, Pathologic / ultrasonography. Reproducibility of Results. Sarcoma, Ewing / pathology. Sarcoma, Ewing / ultrasonography. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ultraschall Med. 2009 Apr;30(2):125-7 [19340726.001]
  • (PMID = 19241505.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


50. Goasguen N, Cattan P, Godiris-Petit G, Munoz-Bongrand N, Allez M, Lemann M, Sarfati E: [Colonic lipoma: case report and literature review]. Gastroenterol Clin Biol; 2008 May;32(5 Pt 1):521-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic lipoma: case report and literature review].
  • [Transliterated title] Lipome colique : cas clinique et revue de la littérature.
  • Colonic lipoma is a rare benign tumor infrequently met in clinical practice.
  • We report a case of symptomatic lipoma of the ascending colon in a 61-year-old woman.
  • [MeSH-major] Colonic Neoplasms. Lipoma

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343069.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 33
  •  go-up   go-down


51. Pasquini P, Baiocchini A, Falasca L, Annibali D, Gimbo G, Pace F, Del Nonno F: Mucosal Schwann cell "Hamartoma": a new entity? World J Gastroenterol; 2009 May 14;15(18):2287-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannoma is a well-described, benign nerve sheath tumor of the soft tissue, but is rare in the gastrointestinal tract.
  • In this report, we describe the clinicopathologic and immunohistochemical features of a distinctive neural mucosal polyp composed of a diffuse cellular proliferation of uniform bland spindled cells in the lamina propria that entraps the colonic crypts.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):431-6 [10199472.001]
  • [Cites] Adv Anat Pathol. 1999 Jan;6(1):19-40 [10197236.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):797-802 [15728600.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1310-5 [16160473.001]
  • [Cites] Histopathology. 2006 Apr;48(5):536-45 [16623779.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):781-7 [19065103.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):111-8 [11356339.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):846-55 [11420455.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Pathol Res Pract. 2002;198(9):605-13 [12440783.001]
  • [Cites] Scand J Gastroenterol. 2003 Dec;38(12):1275-8 [14750649.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):257-64 [3126126.001]
  • [Cites] J Clin Gastroenterol. 1994 Jan;18(1):13-8 [8113577.001]
  • [Cites] Histopathology. 1995 Oct;27(4):355-60 [8847066.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • (PMID = 19437573.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2682248
  •  go-up   go-down


52. Abdul M, Mccray SD, Hoosein NM: Expression of gamma-aminobutyric acid receptor (subtype A) in prostate cancer. Acta Oncol; 2008;47(8):1546-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study, we have investigated, by immunohistochemistry, GABAar levels in 12 normal human prostate, 13 benign prostatic hyperplasia (BPH) and 148 human prostate cancer specimens.
  • [MeSH-minor] Bicuculline / pharmacology. Cell Proliferation / drug effects. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Dihydroergotoxine / pharmacology. GABA Agonists / pharmacology. GABA Antagonists / pharmacology. GABA-A Receptor Agonists. GABA-B Receptor Agonists. Humans. Isonicotinic Acids / pharmacology. Male. Picrotoxin / pharmacology. Prostate / metabolism. Prostate / pathology. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Receptors, GABA-B / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. PICROTOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607852.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR16461
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / GABA Antagonists; 0 / GABA-A Receptor Agonists; 0 / GABA-B Receptor Agonists; 0 / Isonicotinic Acids; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B; 11032-41-0 / Dihydroergotoxine; 124-87-8 / Picrotoxin; Y37615DVKC / Bicuculline; YTF580771Y / isoguvacine
  •  go-up   go-down


53. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL: N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol; 2009 Feb;22(2):182-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a definite immunoprofile of this tumor is missing, the histopathologic diagnosis of intrahepatic cholangiocarcinoma is difficult.
  • The aim of this study was to explore E- and N-cadherin expressions in intrahepatic bile duct tumors, and to determine their potential interest in differential diagnosis.
  • Tissue-microarrays including 20 esophageal, 86 gastric, 8 small bowel, 64 colonic, 18 pancreatic, 6 gallbladder, and 7 extrahepatic biliary tract adenocarcinomas, 22 hepatocellular carcinomas, and normal tissues were constructed.
  • All the benign lesions and 30 of the 45 intrahepatic cholangiocarcinomas (23/29 peripheral and 7/16 hilar) also expressed N-cadherin.
  • The expression of N-cadherin at the plasma membrane of tumor cells was significantly more frequent in peripheral than in hilar intrahepatic cholangiocarcinomas (P=0.003).
  • Among noncholangiocarcinomas, only 1% gastric and 66% gallbladder adenocarcinomas and all the hepatocellular carcinomas expressed N-cadherin at the membrane of tumor cells.
  • In combination with cytokeratin 7 and Hep Par1, N-cadherin is a reliable tool for the histopathological diagnosis of primary hepatic tumors.
  • [MeSH-major] Antigens, CD / analysis. Bile Duct Neoplasms / immunology. Bile Ducts, Intrahepatic / immunology. Biomarkers, Tumor / analysis. Cadherins / analysis. Cholangiocarcinoma / immunology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622386.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KRT7 protein, human; 0 / Keratin-7
  •  go-up   go-down


54. Gold DV, Stein R, Burton J, Goldenberg DM: Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol; 2010;4(1):1-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.
  • For PanIN lesions there was greater expression of CD74 within higher grade, PanIN-3 lesions, whereas the colonic adenomas showed no such trend, but overall, a higher frequency and intensity of CD74 labeling than was observed within the colon carcinomas.
  • These findings are supportive of a role for CD74 in the development and maintenance of gastrointestinal neo-plasia, and provide a rationale for development of therapeutic agents that are able to block CD74 function, specifically within the tumor cell.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Humans. Immunohistochemistry. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1481-9 [15923369.001]
  • [Cites] Cancer Lett. 2001 Jul 10;168(1):87-91 [11368882.001]
  • [Cites] Scand J Immunol. 2001 Jul-Aug;54(1-2):39-44 [11439146.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1467-76 [12782713.001]
  • [Cites] Gene Ther. 2003 Aug;10(17):1512-8 [12900767.001]
  • [Cites] Cancer Immunol Immunother. 2003 Oct;52(10):592-8 [12827305.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5546-50 [15313888.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6606-11 [15475450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Dec;80(24):7395-9 [6324166.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4568-77 [2663143.001]
  • [Cites] Nature. 1990 Jun 14;345(6276):615-8 [2190094.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2391-6 [1527384.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2419-26 [16638847.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6794-801 [16709839.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4807-16 [16484589.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s [17875789.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2784-92 [18056708.001]
  • [Cites] Infect Immun. 2008 Jul;76(7):3233-40 [18474653.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2808-17 [19351768.001]
  • [Cites] Eur J Cancer. 2009 Jun;45(9):1654-63 [19269807.001]
  • [Cites] World J Gastroenterol. 2009 Jun 21;15(23):2855-61 [19533806.001]
  • [Cites] World J Gastroenterol. 2010 Jul 14;16(26):3258-66 [20614481.001]
  • [Cites] J Neurooncol. 2010 Nov;100(2):177-86 [20443131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8581-5 [8397411.001]
  • [Cites] Nature. 1994 Apr 7;368(6471):551-4 [8139689.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):64-71 [8540610.001]
  • [Cites] Biochem J. 1996 Nov 15;320 ( Pt 1):293-300 [8947500.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91 [9192661.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):32-6 [10431843.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3705-11 [15297317.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1254-61 [15477757.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):171-6 [15972644.001]
  • [Cites] Immunology. 1999 Oct;98(2):296-302 [10540230.001]
  • (PMID = 21228923.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096924
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class II; 0 / invariant chain
  • [Other-IDs] NLM/ PMC3016099
  • [Keywords] NOTNLM ; CD74 / colon carcinoma / gastric carcinoma / invariant chain / pancreatic carcinoma
  •  go-up   go-down


55. Saad RS, Silverman JF, Khalifa MA, Rowsell C: CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol; 2009 May;17(3):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CK20/CK7 immunoprofile of colorectal adenocarcinoma has been described in studies, which have mostly lumped colonic and rectal tumors together.
  • CDX2 showed moderate-strong positivity in all cases and was not related to tumor differentiation.
  • Benign rectal mucosa was available in 37 cases and showed the following results: CK7-/CK20+ in 25/37 (67%), CK7+/CK20+ in 8/37 (22%) and CK7-/CK20- in 4/37 (11%) cases.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):464
  • (PMID = 19098678.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


56. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH, Lipkin M: Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis; 2009 Jan;30(1):88-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer.
  • We reported previously that a new Western-style diet (NWD) for 18 months, consisting of elevated lipids and decreased calcium, vitamin D and methyl-donor nutrients, induced colonic tumors in normal C57Bl/6 mice [Newmark, H.L. et al. (2001) A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice.
  • Carcinogenesis, 22, 1871-1875], suggesting a new mouse model for human sporadic colon cancer.
  • Here, we have extended this study during a longer feeding period of 2 years wherein tumor formation, tumor inhibition by addition of dietary calcium and vitamin D and their effects on gene expression were determined.
  • We also similarly tested individual supplements of methyl donor (transfer) nutrients (folic acid, choline, methionine and dietary fiber), but these had no significant effect on colonic tumor incidence or multiplicity, whereas supplementation with combined calcium and vitamin D produced significant decrease in both colon tumor incidence and multiplicity, during 2 years of feeding.
  • No visible colonic tumors were found at 6 months, very few at 12 months, more at 18 months and significantly at 24 months.
  • In a related study of gene changes of the mouse colonic mucosa at 6 months of feeding taken from this study, long before any tumors were visibly detectable, indicated altered profiles of gene expression linked to later risk of dietary initiation of colon tumor formation.
  • This type of early genetic altered profile, an indication of increased risk of later colonic tumor development, may become a useful tool for prediction of colon tumor risk while the colon grossly still appears histologically and physiologically normal.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1871-5 [11698351.001]
  • [Cites] J Nutr. 1977 Jul;107(7):1340-8 [874577.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7803-10 [18829535.001]
  • [Cites] Am J Clin Nutr. 2007 Jun;85(6):1586-91 [17556697.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • (PMID = 19017685.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-05021
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2722141
  •  go-up   go-down


57. Campos FG, Valarini R: Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign diseases were diagnosed in 2356 patients (49.6%).
  • Most diseases were located in 50.7% of the left and sigmoid colon, 28.2% in the rectum and anal canal, 8.0% in the right colon, and diffuse 7.0%.
  • Two thousand three hundred and eighty-nine (50.4%) malignant tumors were operated upon, and histologic classification showed 2347 (98%) adenocarcinomas, 30 (0.6%) spinocelular carcinomas, and 12 (0.2%) other histologic types.
  • Tumor recurrence rate was 16.3% among patients followed more than 1 year.
  • (2) operative indications for benign and malignant diseases were similar, and diverticular disease of the colon comprised 40% of the benign ones;.
  • [MeSH-major] Colectomy / utilization. Colonic Diseases / surgery. Laparoscopy / utilization. Registries

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542856.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Szajda SD, Jankowska A, Zwierz K: Carbohydrate markers in colon carcinoma. Dis Markers; 2008;25(4-5):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate markers in colon carcinoma.
  • Spontaneously mutated multiple oncogenes and/or tumor suppressor genes in colon epithelial cell and its progeny, may cause proliferation out of control and create benign colon neoplasm (colon polyp).
  • If additional mutations involve genes responsible for cell adhesion and movement, aberrant epithelial cells may become malignant (colon cancer) and invade surrounding and remote tissues, creating secondary tumors called metastases.
  • To laboratory detection and monitoring of colon cancer are used tumor markers.
  • Tumor markers are substances produced by the body in response to cancer, or by cancer tissue itself.
  • Glycoconjugate markers for colon cancer include aberrant: mucins covering the surface of the colon epithelial cells, cadherins, selectins and Ig-like adhesion molecules mediating cell-cell adhesion, integrins and integral membrane proteoglycans responsible for adhesion of colon epithelial cells to extracellular matrix, glycoconjugate components of ECM, as well as lysosomal membrane glycoproteins and exoglycosidases.
  • Detection of colon cancer at early non malignant stage is crucial in its prevention and eradication.
  • As colon cancer is the effect of accumulation many somatic mutations in oncogens, supressors, mismatch repair genes and many genes responsible for posttranslational modifications of proteins, multidirectional approach should be applied for its detection.
  • A glycobiological approach to diagnosis and treatment of colorectal cancer should be directed to detection changes in glycosylation accompanying every step of colon cancer progression, and correlation between changes in glycosylation and tumor progression.
  • [MeSH-major] Carbohydrates / chemistry. Carcinoma / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cadherins / chemistry. Cell Adhesion. Disease Progression. Epithelial Cells / metabolism. Glycoproteins / chemistry. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. Polysaccharides / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126967.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Mucins; 0 / Polysaccharides
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3827819
  •  go-up   go-down


59. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


60. Belizon A, Balik E, Horst P, Feingold D, Arnell T, Azarani T, Cekic V, Skitt R, Kumara S, Whelan RL: Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. Surg Endosc; 2008 Feb;22(2):287-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because VEGF is a potent promoter of angiogenesis, which is critical to tumor growth, a sustained increase in blood VEGF levels after surgery may stimulate the growth of residual metastases early after surgery.
  • RESULTS: A total of 49 patients with cancer and 30 patients with benign indications, all of whom underwent minimally invasive colorectal resection, were assessed separately.
  • With regard to the benign patients, the median preoperative VEGF level was 112 pg/ml, and the peak postoperative value, 286 pg/ml, was noted during postoperative week 2.
  • Significant elevations in a similar pattern also were noted for the benign patients.
  • It is possible that the growth of residual tumor deposits may be stimulated early after surgery.
  • [MeSH-major] Colonic Diseases / blood. Colonic Diseases / surgery. Colorectal Neoplasms / blood. Colorectal Neoplasms / surgery. Laparoscopy. Rectal Diseases / surgery. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2008 Feb;22(2):285-6 [17973168.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198.001]
  • [Cites] Surgery. 1999 Jul;126(1):5-9 [10418585.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Anticancer Res. 1992 Sep-Oct;12(5):1603-16 [1444228.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(1):35-40 [16184456.001]
  • [Cites] Dig Surg. 1998;15(2):102-4 [9845570.001]
  • [Cites] Cytokine. 2004 Jan 21;25(2):68-72 [14693162.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Surg Endosc. 2001 Jun;15(6):600-8 [11591950.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):308-14; discussion 308-14 [12632340.001]
  • [Cites] J Biomed Mater Res A. 2005 Sep 15;74(4):659-65 [16035066.001]
  • [Cites] Cancer. 1970 Feb;25(2):362-7 [5413507.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):333-8 [10671682.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Lab Clin Med. 2005 Apr;145(4):194-203 [15962838.001]
  • [Cites] Infect Immun. 1997 Jun;65(6):2283-91 [9169765.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):417-23 [11875709.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1670-4 [15540297.001]
  • [Cites] Gastric Cancer. 2002;5(3):137-41 [12378339.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):36-9 [11961601.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Oncologist. 2007 Mar;12(3):356-61 [17405901.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Angiogenesis. 1999;3(4):335-44 [14517413.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] J Clin Anesth. 2004 Sep;16(6):435-9 [15567647.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • (PMID = 18204877.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


61. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Colon cancer is the third leading cause of cancer-related death in the United States, affecting approximately 147,000 people each year.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations and, more recently, epigenetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and likely drive the histologic progression of colon cancer.
  • Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.
  • These results show that aberrant methylated genes can be detected frequently in sporadic colon polyps and that they can be detected in fecal DNA.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


62. Petersen M, Evert M, Schneider-Stock R, Pross M, Rüschoff J, Roessner A, Lippert H, Meyer F: Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC). Pathol Res Pract; 2009;205(11):801-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic tumor lesions of the pancreas are relatively uncommon.
  • Advances in imaging and pathohistology, including immunohistochemistry, have led to the detection and classification of novel tumor entities.
  • One of these classified cystic neoplasms of the pancreas is serous oligocystic adenoma (SOIA), a rare and benign tumor lesion.
  • He had a medical history significant for subtotal colectomy because of a synchronous double colonic carcinoma.
  • Both tumor tissue specimens had been characterized for a high level of microsatellite instability (MSI) and loss of hMLH1, as well as for a corresponding germ line mutation in hMLH1 gene, leading to the diagnosis of hereditary non-polyposis associated colon cancer (HNPCC).
  • The case is remarkable since the SOIA revealed MSI and loss of hMLH1 protein in the tumor cells that has never been reported for this tumor type.


63. Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW: Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog; 2005 Jun;43(2):65-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line.
  • The organo-specific carcinogen, azoxymethane (AOM), produces colon tumors in mice that share many pathological features with sporadic human colorectal cancer (CRC).
  • To assess the role of the microenvironment in preventing the invasive phenotype, multiple benign in situ adenocarcinomas were harvested from AOM-treated mice and cultured in vitro.
  • However, tumor cell growth was extremely limiting under standard culturing conditions.
  • Thus, we injected tumor cells directly into nude mice and performed two serial transplants, and successfully explanted a rapidly growing epithelial tumor cell line (AJ02nm(0)).
  • When injected subcutaneously (sc) into nude mice, AJ02nm(0) cells formed well-differentiated adenocarcinomas with minimal tumor invasive capacity.
  • AJ02nm-VEGF cells produced rapidly growing tumors in nude mice that exhibited extensive pseudo-epithelial ductal architecture and supporting vasculature, but without increased invasive potential compared to controls.
  • The established murine colon epithelial cell line provides a useful experimental model to further elaborate genetic and epigenetic factors that may promote or inhibit colon tumorigenesis and metastasis.
  • [MeSH-major] Colonic Neoplasms / blood supply. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Antigens, CD31 / analysis. Apoptosis. Cell Division. Cell Line, Tumor. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Karyotyping. Male. Mice. Mice, Inbred A. Mice, Nude. Neoplasm Transplantation. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768385.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 81428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


64. Baratta A, Gorin RJ, Costa R: Sister Mary Joseph nodule: a case report. Cutis; 2007 Dec;80(6):469-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a rare occurrence but may represent the first sign of a visceral malignancy and therefore should prompt a thorough search for the primary tumor.
  • After a full metastatic workup, the tumor of origin was identified as adenocarcinoma of the sigmoid colon.
  • Benign tumors of the umbilicus are uncommon.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Skin Neoplasms / secondary. Umbilicus / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246878.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


66. Jung SH, Paik CN, Jung JH, Lee KM, Chung WC, Yang JM: Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis. Gut Liver; 2009 Sep;3(3):215-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis.
  • Mesenteric fibromatosis (MF) is a rare benign mesenchymal lesion that can occur throughout the gastrointestinal tract, especially small bowel.
  • Its biological behavior is intermediate between benign fibrous tissue proliferation and malignant fibrosarcoma.
  • In previously reported cases of MF, we could find colonic obstruction or ureter obstruction, but simultaneous involvement of colon and ureter was not able to be seen.
  • We described a patient that presented with colonic obstruction and hydroureteronephrosis due to MF at sigmoid colon which mimicked submucosal tumor such as gastrointestinal tumor.
  • This case resulted in a positive positron emission tomography scan suggesting malignant neoplasm, but beta-catenin positivity on immunohistochemical staining separated MF from gastrointestinal stromal tumor and sclerosing mesenteritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Dec 7;13(45):5985-8 [18023087.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):924-6 [17205200.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5226-8 [16127758.001]
  • [Cites] Histopathology. 1994 Nov;25(5):469-73 [7532614.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] AJR Am J Roentgenol. 1991 Aug;157(2):275-9 [1853806.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):335-41 [2321698.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):93-8 [14750246.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1296-301 [12360044.001]
  • [Cites] AJR Am J Roentgenol. 1991 Mar;156(3):539-42 [1899752.001]
  • (PMID = 20431749.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852704
  • [Keywords] NOTNLM ; Colonic obstruction / Hydroureteronephrosis / Mesenteric fibromatosis
  •  go-up   go-down


67. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.
  • In normal stomach and colon, beta3Gn-T6 was strongly expressed in the Golgi region of epithelia.
  • Tissue specimens from a familial adenomatous polyposis patient showed a clear correlation between the down-regulation of beta3Gn-T6 expression and the degree of dysplasia/neoplasia.
  • These results suggested that the expression of beta3Gn-T6 is closely regulated during differentiation and dedifferentiation. beta3Gn-T6 would be a useful marker for distinguishing between benign adenomas and premalignant lesions.
  • [MeSH-major] Colonic Neoplasms / enzymology. Colonic Neoplasms / genetics. N-Acetylglucosaminyltransferases / genetics. N-Acetylglucosaminyltransferases / physiology
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Line, Tumor. Cell Movement / physiology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Down-Regulation. Humans. Immunohistochemistry. In Vitro Techniques. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Transfection

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Anal Biochem. 1976 Aug;74(2):466-76 [962103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2051-5 [6952252.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):231-51 [6576183.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] J Biol Chem. 1985 Jul 15;260(14):8262-71 [4008490.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):1866-74 [3160388.001]
  • [Cites] J Natl Cancer Inst. 1985 Sep;75(3):447-54 [2863413.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15510-5 [4066681.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Soc Biol. 1999;193(1):85-99 [10851560.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L181-7 [11133508.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1043-8 [11292614.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):657-64 [11577689.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):178-86 [11677243.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3834-42 [3288336.001]
  • [Cites] J Biol Chem. 1988 Oct 15;263(29):15146-50 [2971663.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):745-52 [2910493.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1772-82 [1824844.001]
  • [Cites] Genomics. 1991 Oct;11(2):247-51 [1663069.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1199-211 [1312973.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):423-8 [8341719.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):415-24 [8020479.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Glycobiology. 1995 May;5(3):351-7 [7655172.001]
  • [Cites] Eur J Biochem. 1995 Oct 15;233(2):607-17 [7588808.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Cell Biol Int. 1997 May;21(5):281-7 [9243803.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):4916-27 [9538010.001]
  • [Cites] Keio J Med. 1998 Mar;47(1):10-8 [9560527.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):267-74 [9568644.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6817-25 [10346903.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21209-16 [10409676.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12802-9 [11821425.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47724-31 [12361956.001]
  • (PMID = 15755813.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.- / UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC555466
  •  go-up   go-down


68. Nocito A, Hahnloser D: [Indications for laparoscopic colorectal resections--also for cancers?]. Ther Umsch; 2005 Feb;62(2):119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the last decade, laparoscopy has dramatically changed colonic surgery.
  • Laparoscopic procedures are applied to the treatment of almost all colonic diseases, including both benign and malignant lesions.
  • Significant benefits can be expected with a laparoscopic approach relative to decreased pain, ileus, length of hospital stay, disability, and possibly, adhesion formation and subsequent bowel obstruction, and improved cosmesis.
  • However, all those benefits are secondary in the treatment of cancer; tumor-free survival must be the primary goal.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756922.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 73
  •  go-up   go-down


69. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • In addition, biopsies have been taken from the adjacent healthy colon mucosa at least 5 cm from the lesion in each patient.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • The index of Ki-67 expression in healthy colon mucosa at the patients with cholecystectomy was 37,5 +/- 1,8% (p < 0,05) as compared to 31,36 +/- 1,9 at the patients without cholecystectomy.
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


70. Oishi K, Fukuda S, Sakimoto H, Eto T, Takahashi M, Nishida T: Angiomyolipoma of the colon: report of a case. Surg Today; 2009;39(11):998-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiomyolipoma of the colon: report of a case.
  • Angiomyolipomas are benign mesenchymal tumors mostly arising from the kidney.
  • Angiomyolipoma of the colon is extremely rare.
  • Here we report the findings of a 51-year-old man who presented with a submucosal tumor covered with normal mucosa and hemorrhage in the descending colon.
  • He underwent a partial resection of the descending colon.
  • A histopathological examination showed that the tumor of 5.7 cm in diameter included smooth muscle (spindle cell type), mature adipose tissue, and vessels, and therefore a diagnosis of angiomyolipoma was made.
  • A submucosal type of angiomyolipoma of the colon is extremely rare.
  • When colonoscopy shows a submucosal tumor of the colon with hemorrhage, angiomyolipoma should be considered.
  • If an angiomyolipoma of the colon is large, surgical resection should be considered as a treatment option due to the risk of hemorrhage.
  • [MeSH-major] Angiolipoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):523-9 [11914633.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):547-9 [12682553.001]
  • [Cites] Radiology. 2002 Oct;225(1):78-82 [12354988.001]
  • [Cites] Surg Today. 2008;38(6):529-35 [18516533.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1132-6 [10619265.001]
  • [Cites] Radiology. 2004 Mar;230(3):677-84 [14990834.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1852-4 [8792714.001]
  • [Cites] J Urol. 1951 Apr;65(4):525-7 [14825528.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Sep;3(9):A35 [16234016.001]
  • [Cites] Int J Urol. 2005 Feb;12(2):204-7 [15733117.001]
  • [Cites] Gastroenterol Jpn. 1989 Aug;24(4):407-9 [2777016.001]
  • [Cites] Gastrointest Endosc. 2006 Sep;64(3):443-4; discussion 444 [16923501.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1315-25 [12352384.001]
  • [Cites] Radiology. 1997 Nov;205(2):497-502 [9356635.001]
  • (PMID = 19882325.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Weinstein A, Nouri K, Bassiri-Tehrani S, Flores F, Jimenez G: Muir-Torre syndrome: a case of this uncommon entity. Int J Dermatol; 2006 Mar;45(3):311-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to BCC, she had been treated for breast cancer, colon cancer, and cervical cancer prior to emigrating to the USA.
  • Her colonic malignancy had been localized proximal to the splenic flexure.
  • She also had a history of colonic polyps and distal colonic villous adenoma.
  • Her family history was significant for a sister with colon cancer and transitional cell carcinoma of the urinary bladder.
  • No further treatment was required for these benign sebaceous tumors, but their presence defined our patient's condition as Muir-Torre syndrome.
  • Mohs' micrographic surgery was performed on the tragus BCC and the margins were tumor free in one stage.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Basal Cell / complications. Colonic Neoplasms / complications. Skin Neoplasms / complications. Uterine Cervical Neoplasms / complications


72. Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem; 2006 Nov 17;281(46):34936-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on tumor progression in animal models.
  • On the other hand, inhibition of constitutive HA-tumor cell interactions in malignant cells inhibits these properties.
  • IGF1R-beta, PDGFR-beta, EGFR and c-MET, in colon, prostate, and breast carcinoma cells.
  • On the other hand, we show that these RTKs are activated in phenotypically normal or relatively benign tumor cells by experimentally increasing HA production.
  • In HCA7 colon and C4-2 prostate carcinoma cells, ERBB2 is constitutively activated in a ligand-independent manner, whereas IGF1R-beta and PDGFR-beta require ligand interaction for activation.
  • [MeSH-minor] Breast Neoplasms / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Humans. Male. Prostatic Neoplasms / metabolism. Signal Transduction


73. Chen YY, Soon MS: Preoperative diagnosis of colonic angiolipoma: a case report. World J Gastroenterol; 2005 Aug 28;11(32):5087-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative diagnosis of colonic angiolipoma: a case report.
  • Angiolipoma, a common benign tumor mostly seen in the subcutaneous tissue, is a rare pathological condition in the gastrointestinal tract that is usually diagnosed postoperatively.
  • [MeSH-major] Angiolipoma / radiography. Colonic Neoplasms / radiography. Preoperative Care. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. Barium, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16124075.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 24GP945V5T / Barium
  • [Other-IDs] NLM/ PMC4321939
  •  go-up   go-down


74. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M: Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun; 2005 Jul 8;332(3):800-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer.
  • Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells.
  • COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry.
  • Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition.
  • Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2.
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Colonic Neoplasms / metabolism. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dinoprostone / biosynthesis. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Male. Membrane Proteins. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907789.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 69533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


75. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We find that epithelial cells of human colon carcinomas (CCs) and their stem cells of all stages harbour an active HH-GLI pathway.
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Targeting HH-GLI1, directly or indirectly, is thus predicted to decrease tumour bulk and eradicate CC stem cells and metastases.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Epithelial Cells / metabolism. Hedgehog Proteins / metabolism. Neoplastic Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


76. Pagnotta E, Calonghi N, Boga C, Masotti L: N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells. Anticancer Drugs; 2006 Jun;17(5):521-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells.
  • Both agents show the same anti-proliferative effects by arresting colon cancer cell growth in G0/G1.
  • The effects of NMF and 9-HSA on growth, differentiation and invasiveness of HT29, a colon cancer cell line, have been compared by using immunoprecipitation analysis, confocal microscopy, enzyme assays and invasiveness tests.
  • Evidence is presented that the arrest in early G0/G1 induced by 9-HSA is associated with the conversion of HT29 characteristics to those of a more benign phenotype, whereas the arrest in the late G1 in response to NMF is not followed by a decrease in tumorigenicity.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Formamides / pharmacology. Stearic Acids / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cytoskeleton / drug effects. Humans. Microscopy, Confocal

  • Hazardous Substances Data Bank. N-METHYLFORMAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702808.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Formamides; 0 / Stearic Acids; 3384-24-5 / 9-hydroxystearic acid; XPE4G7Y986 / methylformamide
  •  go-up   go-down


77. Sieren LM, Collins JN, Weireter LJ, Britt RC, Reed SF, Novosel TJ, Britt LD: The incidence of benign and malignant neoplasia presenting as acute appendicitis. Am Surg; 2010 Aug;76(8):808-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of benign and malignant neoplasia presenting as acute appendicitis.
  • We sought to review our experience with neoplasia presenting as appendicitis.
  • Ten patients (7.1%) were diagnosed with neoplasia on final pathology, including four women and six men with a mean age of 46.9 years and mean duration of symptoms of 12.6 days.
  • Final pathology revealed four colonic adenocarcinoma; three mucinous tumors; one carcinoid; one endometrioma; and one patient had a combination of a mucinous cystadenoma, a carcinoid tumor, and endometriosis of the appendix.
  • Colonic and appendiceal neoplasia are not unusual etiologies of appendicitis.

  • MedlinePlus Health Information. consumer health - Appendicitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726408.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Matsumoto T, Hirano S, Yada K, Shibata K, Sasaki A, Kamimura T, Ohta M, Kitano S, Kashima K: Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature. J Clin Gastroenterol; 2005 Mar;39(3):253-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature.
  • BACKGROUND: In general, serous cystic neoplasms of the pancreas are thought to be benign.
  • Malignant serous cystic neoplasm of the pancreas is a rare clinical entity.
  • CASE REPORT: We report the case of an 87-year-old woman with a serous microcystic neoplasm in the tail of the pancreas that behaved in a malignant fashion.
  • The neoplasm had also invaded the colonic mesentery and splenic hilum.
  • The pancreatic lesion was diagnosed as a large malignant serous cystic neoplasm, and the patient underwent distal pancreatectomy with splenectomy and segmental colectomy.
  • The resected specimen contained a large tumor, 12 x 9 x 8 cm, which occupied the body and tail of the pancreas.
  • Histologically, the tumor was indistinguishable from serous cystadenoma.
  • However, the tumor had invaded surrounding tissues including the splenic vein, and there were splenic invasion and a regional lymph node metastasis.
  • DISCUSSION: There are few reported cases of malignant serous cystic neoplasm, in which malignancy was histologically confirmed in the resected specimen.
  • There are no reports of a negative outcome with complete resection of the tumor.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718870.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


79. Coons SW, Estrada SI, Gamez R, White WL: Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr Pathol; 2005;16(3):201-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because pituitary tumors are almost always benign, there has been little interest in their cytokeratin profile.
  • However, we recently reported the use of CK 7/20 expression to document malignant progression and metastasis of a pituitary tumor, indicating the potential diagnostic usefulness of the CK 7/20 profile of pituitary adenomas.
  • This CK 20-positive, CK 7-negative profile is previously described consistently only in colonic adenocarcinomas.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Intermediate Filament Proteins / metabolism. Keratins / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):13-43, v-vi [10207684.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):764-7 [7528468.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):119-26 [9490269.001]
  • [Cites] Mod Pathol. 1995 May;8(4):384-8 [7567935.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):171-7 [9921990.001]
  • [Cites] Endocr Pathol. 1996 Summer;7(2):145-150 [12114642.001]
  • (PMID = 16299403.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


80. Huo Q: Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay. Colloids Surf B Biointerfaces; 2010 Jul 1;78(2):259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study examined four biomarkers proteins, CA125, CEA (carcinoembryonic antigen), CA19-9 and PAP (prostatic acid phosphatase) in ovarian, colon and prostate tissue lysates.
  • The most exciting results were observed from the PAP assay of prostate tissues: prostate cancer can be clearly distinguished from normal prostate and prostate with benign conditions such as BPH (benign prostate hyperplasia) based on the complex/aggregation level of PAP in prostate tissue lysates.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunoassay / methods. Metal Nanoparticles / chemistry. Neoplasms / metabolism. Proteins / analysis
  • [MeSH-minor] Acid Phosphatase. Adult. Aged. Aged, 80 and over. Antibodies / chemistry. CA-125 Antigen / analysis. CA-125 Antigen / chemistry. CA-19-9 Antigen / analysis. CA-19-9 Antigen / chemistry. Carcinoembryonic Antigen / analysis. Carcinoembryonic Antigen / chemistry. Colonic Neoplasms / diagnosis. Colonic Neoplasms / metabolism. Diagnosis, Differential. Female. Gold / chemistry. Humans. Male. Membrane Proteins / analysis. Membrane Proteins / chemistry. Middle Aged. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism. Protein Binding. Protein Conformation. Protein Tyrosine Phosphatases / analysis. Protein Tyrosine Phosphatases / chemistry. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20392611.001).
  • [ISSN] 1873-4367
  • [Journal-full-title] Colloids and surfaces. B, Biointerfaces
  • [ISO-abbreviation] Colloids Surf B Biointerfaces
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / MUC16 protein, human; 0 / Membrane Proteins; 0 / Proteins; 7440-57-5 / Gold; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


81. Gobet R, Weber D, Renzulli P, Kellenberger C: Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome. J Pediatr Urol; 2009 Jun;5(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient suffered from adenocarcinoma of the colon, five had benign colonic polyps, one urethral papillary carcinoma and 18 no evidence of tumor.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Aged. Carcinoma, Papillary / epidemiology. Child. Child, Preschool. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urination. Urolithiasis / epidemiology

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136304.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Lethal giant larvae (lgl) gene controls apical-basal polarity of epithelial cells in Drosophila, and has properties of a tumor-suppressor gene.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


83. Hajdú N, Zsoldos P, Neuberger G: [Rectum tumor diagnosed by subcutaneous emphysema of the chest]. Magy Seb; 2009 Oct;62(5):308-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectum tumor diagnosed by subcutaneous emphysema of the chest].
  • BACKGROUND: Various benign and malignant thoracic or abdominal diseases can cause subcutaneous emphysema on the chest, pneumomediastinum or pneumopericardium.
  • To date only 7 cases have been reported on perforation of the sigmoid colon or the rectum presenting with these rare symptoms.
  • Further examination revealed that this was caused by a rectal tumor causing large bowel obstruction and a consequent perforation of the transverse colon.
  • [MeSH-major] Colonic Diseases / surgery. Intestinal Obstruction / surgery. Rectal Neoplasms / complications. Rectal Neoplasms / diagnosis. Subcutaneous Emphysema / etiology


84. Olesen SH, Christensen LL, Sørensen FB, Cabezón T, Laurberg S, Orntoft TF, Birkenkamp-Demtröder K: Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics; 2005 Apr;4(4):534-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a previously published microarray study an EST (W80763), later identified as the gene hFKBP10 (NM_021939), was found to be strongly expressed in tumors while absent in the normal mucosa.
  • Analysis of 31 colorectal adenocarcinomas and 14 normal colorectal mucosa by RealTime PCR for hFKBP10 showed a significant up-regulation in tumors, when compared with normal mucosa.
  • Immunohistochemical analysis of 26 adenocarcinomas and matching normal mucosa, as well as benign hyperplastic polyps and adenomas, using a monoclonal anti-hFKBP65 antibody, showed that the protein was not present in normal colorectal epithelial cells, but strongly expressed in the tumor cells of colorectal cancer.
  • The protein was also expressed in fibroblasts of both normal mucosa and tumor tissue.
  • Western blot analysis of matched tumors and normal mucosa supported the finding of increased hFKBP65 expression in tumors compared with normal mucosa, in addition to identifying the molecular mass of hFKBP65 to approximately 72 kDa.
  • [MeSH-minor] Adenoma / pathology. Aged. Aged, 80 and over. Amino Acid Sequence. Animals. Antibodies, Monoclonal / metabolism. Binding Sites. Blotting, Western. COS Cells. Cercopithecus aethiops. Colonic Polyps / pathology. Electrophoresis, Gel, Two-Dimensional. Electrophoresis, Polyacrylamide Gel. Female. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia. Immunohistochemistry. Intestinal Mucosa / cytology. Isoelectric Point. Male. Microscopy, Fluorescence. Middle Aged. Molecular Sequence Data. Molecular Weight. Polymerase Chain Reaction. Protein Binding. Transfection

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671042.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 5.2.1.- / Tacrolimus Binding Proteins
  •  go-up   go-down


85. Merchant NB, Parikh AA, Kooby DA: Should all distal pancreatectomies be performed laparoscopically? Adv Surg; 2009;43:283-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are both enough experience and data (though retrospective) to confirm that LDP with or without spleen preservation appears to be a safe treatment for benign or noninvasive lesions of the pancreas.
  • Based on the fact that LDP can be performed with similar or shorter operative times, blood loss, complication rates, and length of hospital stay than ODP, it can be recommended as the treatment of choice for benign and noninvasive lesions in experienced hands when clinically indicated.
  • It is very difficult to make clear recommendations with regard to laparoscopic resection of malignant pancreatic tumors due to the lack of conclusive data.
  • Can we enucleate a small tumor off the pancreatic body by passing an endoscope through the gastric (or colonic) wall, and bring the specimen out via the mouth or anus?

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845186.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


86. Elkharwily A, Gottlieb K: The pancreas in familial adenomatous polyposis. JOP; 2008;9(1):9-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adenomatous polyposis coli gene functions as a tumor suppressor with hundreds of known mutations that result in a defective adenomatous polyposis coli protein.
  • In addition to the certain fate of colon cancer without colectomy, patients with familial adenomatous polyposis are also at increased risk for other types of neoplasms, including those which affect the pancreas.
  • This review focuses on periampullary and ampullary tumors, benign and malignant pancreatic neoplasms that are associated with familial adenomatous polyposis and Gardner syndrome and pancreatitis in these patients.
  • [MeSH-minor] Ampulla of Vater / pathology. Colonic Neoplasms / epidemiology. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Humans. Pancreatitis / epidemiology. Pancreatitis / pathology. Risk Factors


87. Carvalho J, Fullen D, Lowe L, Su L, Ma L: The expression of CD23 in cutaneous non-lymphoid neoplasms. J Cutan Pathol; 2007 Sep;34(9):693-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its utility in cutaneous epithelial tumors has never been studied.
  • METHODS: Immunohistochemical staining of CD23 was performed in a total of 131 cases of apocrine, eccrine, follicular and other cutaneous non-lymphoid tumors.
  • RESULTS: CD23 expression was detected in all benign apocrine tumors and in half of benign eccrine tumors, particularly those derived from secretory coils.
  • CD23 staining was seen in 42% (8/19) of microcystic adnexal carcinoma (MAC), while no staining was observed in tumor cells of desmoplastic trichoepithelioma, morpheaform basal cell carcinoma and syringoma.
  • In addition, CD23 reacted diffusely with cutaneous mucinous eccrine carcinoma in a manner similar to breast or colonic adenocarcinoma.
  • CONCLUSION: CD23 appears to be a reliable immunohistochemical marker of the eccrine/apocrine secretory coil and helpful in identifying sweat gland tumors of such origin.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Receptors, IgE / metabolism. Sweat Gland Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696916.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, IgE
  •  go-up   go-down


88. Grieco MJ, Shantha Kumara HM, Baxter R, Dujovny N, Kalady MF, Cekic V, Luchtefeld M, Whelan RL: Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting. Surg Endosc; 2010 Oct;24(10):2617-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting.
  • BACKGROUND: Epidermal growth factor (EGF) stimulates tumor growth directly via tumor cell EGF receptors or indirectly via its proangiogenic effects.
  • This study's purpose was to determine the impact of minimally invasive colorectal resection (MICR) on postoperative (postop) plasma EGF levels in the colorectal cancer (CRC) and benign disease settings and to see if preoperative (PreOp) EGF levels are altered in cancer patients.
  • METHODS: MICR patients with benign pathology (n = 40) and CRC (n = 48) had blood samples taken PreOp and on postoperative days (POD) 1 and 3.
  • RESULTS: The cancer and benign groups were comparable except for age.
  • The mean PreOp CRC plasma EGF level (122.9 ± 75.9 pg/ml) was significantly higher than that of the benign group (85.3 ± 38.5 pg/ml) (p = 0.015).
  • The benign group's POD3 and POD7-14 EGF levels were significantly lower than the PreOp level; later levels returned toward baseline.
  • MICR is associated with a significant decrease in EGF levels early postop in both cancer and benign settings.
  • Unlike the benign group, EGF blood levels in cancer patients remain low during the second postop month.
  • EGF may have value as a tumor marker.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Epidermal Growth Factor / blood. Laparoscopy
  • [MeSH-minor] Aged. Colonic Diseases / blood. Colonic Diseases / surgery. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Aug;25(8):2766-7; author reply 2768 [21416177.001]
  • [Cites] Cancer Res. 1974 Aug;34(8):2109-13 [4842257.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):283-7 [8631552.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5119-23 [3044581.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3823-30 [8706030.001]
  • [Cites] Gut. 1996 Apr;38(4):582-6 [8707092.001]
  • [Cites] Int J Cancer. 1990 Jun 15;45(6):1018-21 [2351482.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3716-25 [15867367.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):973-7 [19474682.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1293-6 [9137488.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):613-9 [9066588.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):162-5 [8391303.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):121-33 [7680247.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):353-62 [16474912.001]
  • [Cites] Surgery. 2003 Sep;134(3):432-6 [14555930.001]
  • [Cites] J Clin Invest. 1992 Oct;90(4):1352-60 [1401070.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):8-13 [1624295.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):186-94 [10638988.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1523-30 [9403702.001]
  • (PMID = 20354877.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


89. Zhang X, Leav I, Revelo MP, Deka R, Medvedovic M, Jiang Z, Ho SM: Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet; 2009 Jan;5(1):e1000334
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
  • Alpha-methylacyl-coenzyme A racemase (AMACR) regulates peroxisomal beta-oxidation of phytol-derived, branched-chain fatty acids from red meat and dairy products -- suspected risk factors for colon carcinoma (CCa).
  • AMACR was first found overexpressed in prostate cancer but not in benign glands and is now an established diagnostic marker for prostate cancer.
  • By using a panel of immunostained-laser-capture-microdissected clinical samples comprising the entire colon adenoma-carcinoma sequence, we show that deregulation of AMACR during colon carcinogenesis involves two nonrandom events, resulting in the mutually exclusive existence of double-deletion at CG3 and CG10 and deletion of CG12-16 in a newly identified CpG island within the core promoter of AMACR.
  • It existed in histologically normal colonic glands and tubular adenomas with low AMACR expression and was absent in villous adenomas and all CCas expressing variable levels of AMACR.
  • Our findings identified key in vivo events and novel transcription factors responsible for AMACR regulation in CCas and suggested these AMACR deletions may have diagnostic/prognostic value for colon carcinogenesis.
  • [MeSH-major] Colon / enzymology. Colonic Neoplasms / genetics. CpG Islands / genetics. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic. Racemases and Epimerases / genetics
  • [MeSH-minor] Adenoma, Villous / genetics. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Base Sequence. Binding Sites. Cell Differentiation. Cell Line, Tumor. Humans. Molecular Sequence Data. Polymorphism, Genetic. Repressor Proteins / metabolism. Sequence Deletion / genetics. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15685-90 [10748193.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Lipid Res. 2002 Mar;43(3):438-44 [11893780.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8 [12229925.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] J Lipid Res. 2003 May;44(5):968-77 [12611910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):775-83 [12917210.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Cancer Detect Prev. 2003;27(6):422-6 [14642549.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):47-53 [14689581.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):787-93 [14982833.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Cell. 1980 Oct;21(3):653-68 [6985477.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):386-9 [1592529.001]
  • [Cites] Genome Res. 2007 Jun;17(6):807-17 [17567999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1487-97 [17680641.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1507-13 [17683075.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7346-54 [17525739.001]
  • [Cites] Environ Health Perspect. 2008 Jun;116(6):769-76 [18560533.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1763-77 [18836037.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;301:259-81 [16570852.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1325-33 [1463014.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):881-5 [9175734.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1283-7 [10098773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2970-4 [15710887.001]
  • [Cites] Mol Cancer Res. 2005 Feb;3(2):110-8 [15755877.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2933-42 [15860560.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):252-5 [16082251.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1410-5 [16105129.001]
  • [Cites] Clin Transl Oncol. 2006 Jun;8(6):391-8 [16790391.001]
  • [Cites] Atherosclerosis. 2006 Sep;188(1):43-50 [16289551.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):41-50 [17315319.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):850-6 [17442371.001]
  • [Cites] J Med Chem. 2007 May 31;50(11):2700-7 [17477519.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):175-80 [17525630.001]
  • (PMID = 19148275.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112532; United States / NCI NIH HHS / CA / R01 CA112532; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NCI NIH HHS / CA / R01 CA062269; United States / NCI NIH HHS / CA / CA062269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / ZNF202 protein, human; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2613032
  •  go-up   go-down


90. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • METHODS: The expression of XAF1 in four human colon cancer cell lines (Colo205, Colo320, SW1116, LoVo) and in samples from 70 patients with CRC was analyzed by reverse transcriptase-polymerase chain reaction.
  • RESULTS: A low concentration of XAF1 mRNA was detectable in the three colon cancer cell lines other than Colo205, which showed the strongest expression of XAF1.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


91. Tedesco MM, Curet MJ: Laparoscopic-assisted colectomy for colon cancer. Expert Rev Med Devices; 2006 Jul;3(4):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted colectomy for colon cancer.
  • Laparoscopic-assisted colectomy (LAC) for colon cancer was first described in 1991.
  • Unlike other laparoscopic procedures used to treat benign disease, the LAC for colon cancer has been slow to gain acceptance for a variety of reasons.
  • Recently, several large, randomized controlled trials have demonstrated that LACs are comparable with open colectomies with respect to oncological issues such as survival, port-site metastases and tumor recurrence.
  • Moreover, there are significant patient benefits with the use of LAC including duration of analgesic use, return of bowel function, length of stay and return to normal activity.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Humans. Length of Stay. Neoplasm Recurrence, Local. Quality of Life. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866638.001).
  • [ISSN] 1743-4440
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


92. Sheehan CE, Bartlett MB, Ganesan N, Preet A, Ross JS, FitzGerald KT: Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int; 2010 Apr 30;10:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon.
  • In light of this difference, and previous reports on involvement of epigenetic regulators in malignancies, we investigated MLL2 expression in established cell lines from breast and colon tissues.
  • We then investigated MLL2 in solid tumors of breast and colon by immunohistochemistry, and evaluated potential associations with established clinicopathologic variables.
  • RESULTS: We examined MLL2 at both transcript and protein levels in established cell lines from breast and colon cancers.
  • Furthermore, we also identified incomplete proteolytic cleavage of MLL2 in the highly invasive tumor cell lines.
  • To corroborate these results, we studied tumor tissues from patients by immunohistochemistry.
  • Patient samples also revealed increased levels of MLL2 protein in invasive carcinomas of the breast and colon.
  • In breast, cytoplasmic MLL2 was significantly increased in tumor tissues compared to adjacent benign epithelium (p < 0.05), and in colon, both nuclear and cytoplasmic immunostaining was significantly increased in tumor tissues compared to adjacent benign mucosa (p < 0.05).
  • CONCLUSION: Our study indicates that elevated levels of MLL2 in the breast and colon cells are associated with malignancy in these tissues, in contrast to MLL involvement in haematopoietic cancer.
  • In addition, both abnormal cellular localization of MLL2 and incomplete proteolytic processing may be associated with tumor growth/progression in breast and colonic tissues.

  • Genetics Home Reference. consumer health - KMT2D gene.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1978 May;38(5):1345-55 [565251.001]
  • [Cites] Proc R Soc Med. 1937 Feb;30(4):371-6 [19990989.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):815-21 [1381724.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3401-6 [2720694.001]
  • [Cites] Genomics. 1999 Jul 15;59(2):187-92 [10409430.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):7975-84 [10637508.001]
  • [Cites] Trends Biochem Sci. 2002 Aug;27(8):396-402 [12151224.001]
  • [Cites] Breast Cancer Res. 2003;5(2):89-95 [12631387.001]
  • [Cites] Trends Genet. 2003 Nov;19(11):629-39 [14585615.001]
  • [Cites] Science. 2003 Dec 12;302(5652):1972-5 [14671306.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):587-97 [14992727.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):701-7 [15375488.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):1054-65 [15743678.001]
  • [Cites] Development. 2006 Apr;133(8):1423-32 [16540515.001]
  • [Cites] Acta Oncol. 2006;45(4):375-88 [16760173.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1265-72 [16797254.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2397-409 [16951254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15392-7 [17021013.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Nutrition. 2007 Jan;23(1):81-6 [17189090.001]
  • [Cites] Mol Biol Cell. 2007 Jun;18(6):2356-66 [17429066.001]
  • [Cites] Mol Cell. 2007 Aug 17;27(4):573-84 [17707229.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):77-84 [18066051.001]
  • [Cites] Mol Endocrinol. 2008 Jun;22(6):1312-9 [18372346.001]
  • [Cites] J Biol Chem. 2008 Dec 12;283(50):35258-64 [18840606.001]
  • [Cites] Epigenetics Chromatin. 2009;2(1):5 [19348672.001]
  • [Cites] J Natl Cancer Inst. 1977 Feb;58(2):209-14 [833871.001]
  • (PMID = 20433758.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2878298
  •  go-up   go-down


93. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


94. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4283-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative lesion sequencing provides insights into tumor evolution.
  • We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common.
  • When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize;.
  • (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells.
  • These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] World J Surg. 2004 Mar;28(3):263-70 [14961200.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Humangenetik. 1972;16(1):87-110 [4647448.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1650-5 [6299526.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6109-14 [3167857.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):968-71 [2159442.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):60-6 [1998868.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):435-41 [7640229.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cytometry. 1997 Nov 1;29(3):273-8 [9389445.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):213-22 [9748584.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):803-11 [10091757.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1963 Oct;90:673-87 [14068399.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8111-7 [16166284.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):610-4 [16582617.001]
  • [Cites] Cancer Sci. 2006 May;97(5):362-7 [16630132.001]
  • [Cites] Nat Methods. 2006 Jul;3(7):551-9 [16791214.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227 [17178965.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Nat Protoc. 2006;1(2):859-69 [17406318.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 [12857956.001]
  • (PMID = 18337506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R01 CA127306; United States / NCI NIH HHS / CA / CA121113; United States / NIGMS NIH HHS / GM / GM078986; United States / NCI NIH HHS / CA / CA127306; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIGMS NIH HHS / GM / R01 GM078986; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R01 CA120237; United States / NCI NIH HHS / CA / R01 CA121113; United States / NIGMS NIH HHS / GM / GM078986-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043703; United States / NCI NIH HHS / CA / CA120237; United States / NCI NIH HHS / CA / U54 CA116867; United States / NIGMS NIH HHS / GM / R01 GM078986-02; United States / NCI NIH HHS / CA / CA116867; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA105090
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2393770
  •  go-up   go-down


95. Zmora O, Benjamin B, Reshef A, Neufeld D, Rosin D, Klein E, Ayalon A, Shpitz B: Laparoscopic colectomy for colonic polyps. Surg Endosc; 2009 Mar;23(3):629-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for colonic polyps.
  • BACKGROUND: Benign colonic polyps not amenable to colonoscopic resection or those containing carcinoma require surgical excision.
  • The aim of this study was to review our experience with the laparoscopic approach for retrieval of colonic polyps with specific emphasis on safety, feasibility, and tumor localization.
  • METHODS: Retrospective chart review of all patients who underwent laparoscopic colectomy for colonic polyps was performed.
  • RESULTS: Forty-nine patients (22 males, 27 males, mean age 66 years) underwent laparoscopic colectomy for colonic polyps.
  • Indications for surgery were presumably benign polyps in 38 patients, and superficial carcinoma in a polyp, diagnosed by colonoscopy, in 11; twenty-three patients underwent preoperative localization procedures.
  • In 7 of the 38 patients with presumably benign lesion, colon cancer was diagnosed in the colectomy specimen.
  • CONCLUSIONS: Laparoscopic surgery for the treatment of colonic polyps seems to be feasible and safe, with a low complication rate.
  • Tumor localization is crucial for adequate resection.
  • Although one-fifth of presumably benign polyps harbored cancer, none of these patients had positive lymph nodes.
  • [MeSH-major] Colectomy / methods. Colonic Polyps / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Apr;30(4):605-11 [16555023.001]
  • [Cites] Surg Endosc. 2002 May;16(5):808-11 [11997827.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1111-24 [15449261.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):177-81 [12892794.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1491-5 [17534547.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1353-5 [10528779.001]
  • [Cites] Ann Surg. 2006 Jun;243(6):730-5; discussion 735-7 [16772776.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003145 [16034888.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1197-9 [18062067.001]
  • [Cites] Dis Colon Rectum. 1999 Jun;42(6):819-22 [10378609.001]
  • [Cites] Am J Surg. 2006 Nov;192(5):644-8 [17071200.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • (PMID = 19067054.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


96. Lebeau R, Koffi E, Diané B, Amani A, Kouassi JC: [Acute intestinal intussusceptions in adults: analysis of 20 cases]. Ann Chir; 2006 Oct;131(8):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Invaginations intestinales aiguës de l'adulte: analyse d'une série de 20 cas.
  • The clinical and radiological findings were suggestive of bowel obstruction (N = 14), peritonitis (N = 5) and appendicular abscess (N = 1).
  • Necrosis was found in the intussusceptum in 10 cases and a tumor on the lead point in 14 cases (5 benign lesions and 9 malignant ones).
  • For intussusception involving the colon, all patients underwent en bloc resection with immediate anastomosis, while intussusception located on the small bowel were treated by surgical reduction (N = 1), en bloc resection (N = 8) with immediate (N = 7) or delayed (N = 1) anastomosis.
  • En bloc resection is recommended because of the frequency of neoplasms and bowel ischemia.
  • [MeSH-major] Colonic Diseases / surgery. Ileal Diseases / surgery. Ileocecal Valve. Intussusception / surgery. Jejunal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765901.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


97. Pulitzer M, Xu R, Suriawinata AA, Waye JD, Harpaz N: Microcarcinoids in large intestinal adenomas. Am J Surg Pathol; 2006 Dec;30(12):1531-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Composite adenoma-carcinoid tumors are rare colorectal lesions consisting of intermingled adenomatous and carcinoid components.
  • Unlike other mixed endocrine-glandular colorectal neoplasms, which are generally malignant, their glandular component is histologically benign and their natural history is favorable.
  • We present 4 cases of colonic adenomas containing microcarcinoids, a hitherto undescribed lesion that is either a precursor of composite adenoma-carcinoids or a related but independent entity.
  • The cases, identified among our surgical and consultation files, were endoscopically routine sessile polyps removed from 4 otherwise normal individuals, 3 from the cecum and 1 from the distal colon.
  • The patients' clinical course was benign on the basis of 2 years' median follow-up (range, 6 mo to 10 y).
  • Two patients with incomplete polypectomies underwent hemicolectomy revealing no residual endocrine neoplasia.
  • Awareness of microcarcinoids in colonic adenomas should help avert potential diagnostic pitfalls posed by their pleomorphism, basal location, and infiltrative patterns, and may help clarify their natural history and possible relationship to composite glandular-carcinoid tumors.
  • [MeSH-major] Adenoma / pathology. Carcinoid Tumor / pathology. Intestinal Neoplasms / pathology. Intestine, Large / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122508.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Van Patten K, Parkash V, Jain D: Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. Mod Pathol; 2010 Jan;23(1):38-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 38 cases (peritoneal endometriosis (n=14), gastrointestinal endometriosis (n=21: 11 colon, 8 appendix, 2 small bowel), and 3 cases of endometrioid carcinoma arising in colonic endometriosis (n=3)) were included in the study.
  • All three cases of carcinoma arising in colonic endometriosis showed a total loss of N-cadherin in the tumor, but preserved E-cadherin and beta-catenin expression.
  • In these cases, areas of benign endometriotic glands near the tumor showed weak and focal N-cadherin expression that was gradually lost.


99. Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN: ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle; 2008 Jun 1;7(11):1640-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer.
  • Recently, however, the abundance of ARC was noted to be markedly increased in the epithelium of primary human breast cancers compared with benign breast tissue and to confer chemo- and radiation-resistance.
  • Whether the induction of ARC is specific to breast cancer or a more general feature of neoplasia remains unknown.
  • In this study, we assessed the abundance and subcellular localization of ARC in 21 human colon cancer cell lines and in 44 primary human colon adenocarcinomas and adjacent benign colonic tissue.
  • ARC was present at high levels in most colon cancer cell lines and in almost all primary colon cancers compared with corresponding controls.
  • Levels of ARC in the cytoplasm were increased in well, moderately, and poorly differentiated cancers compared with benign tissue, while levels of nuclear ARC were increased only in moderately differentiated tumors.
  • These results demonstrate that ARC is a novel marker of human colon cancer and suggest that it may be a general feature of epithelial cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis Regulatory Proteins / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / metabolism. Muscle Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Cytoplasm / metabolism. Humans. Immunoblotting. Immunohistochemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469522.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NHLBI NIH HHS / HL / R01HL60665; United States / NHLBI NIH HHS / HL / R01HL61550; United States / NHLBI NIH HHS / HL / R01HL80607
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / NOL3 protein, human
  •  go-up   go-down


100. Bonin EA, Baron TH: Update on the indications and use of colonic stents. Curr Gastroenterol Rep; 2010 Oct;12(5):374-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the indications and use of colonic stents.
  • Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.
  • Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.
  • Colonic stent placement also offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications.
  • Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.
  • Colorectal stents have also been used in selected patients with benign colonic strictures.
  • Patients with benign colonic stricture with acute colonic obstruction who are at high risk for emergency surgery can gain temporary relief of obstruction after SEMS placement; the stent can be removed en bloc with the colon specimen at surgery.
  • This article reviews the techniques and indications of SEMS placement for benign and malignant colorectal obstructions.
  • [MeSH-minor] Acute Disease. Colon / pathology. Colon / surgery. Colonic Diseases / etiology. Colonic Diseases / surgery. Constriction, Pathologic / surgery. Humans. Palliative Care. Pelvic Neoplasms / complications. Pelvic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2009 Oct;19(5):e202-5 [19851253.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):178-83 [18477021.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1573-4 [17084754.001]
  • [Cites] Scand J Surg. 2009;98(3):143-7 [19919918.001]
  • [Cites] J Gastrointest Surg. 2009 May;13(5):960-5 [19159986.001]
  • [Cites] South Med J. 2009 Dec;102(12):1257-9 [20016435.001]
  • [Cites] World J Surg. 2009 Jun;33(6):1281-6 [19363580.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):68-73 [18028916.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):719-25 [11400965.001]
  • [Cites] Brachytherapy. 2009 Jul-Sep;8(3):313-7 [19211311.001]
  • [Cites] Can J Gastroenterol. 2006 Dec;20(12):779-85 [17171197.001]
  • [Cites] Arch Surg. 2009 Dec;144(12):1127-32 [20026830.001]
  • [Cites] Surg Endosc. 2007 Feb;21(2):225-33 [17160651.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):799-805 [20363422.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):560-72 [20189515.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jul;193(1):248-54 [19542421.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):24-30 [12544518.001]
  • [Cites] World J Gastroenterol. 2007 Aug 7;13(29):3977-80 [17663513.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):293-7 [19508834.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Jan;25(1):50-4 [19119510.001]
  • [Cites] Scand J Gastroenterol. 2010 Jun;45(6):725-31 [20205505.001]
  • [Cites] Colorectal Dis. 2009 May;11(4):405-9 [18513190.001]
  • [Cites] Radiology. 2010 Mar;254(3):774-82 [20177092.001]
  • [Cites] Dis Colon Rectum. 2009 Sep;52(9):1657-61 [19690497.001]
  • [Cites] Dis Colon Rectum. 2009 Jul;52(7):1272-7 [19571704.001]
  • [Cites] J Am Coll Surg. 2010 Jan;210(1):45-53 [20123331.001]
  • [Cites] BMC Surg. 2007 Jul 03;7:12 [17608947.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Am Surg. 2009 Oct;75(10):897-900 [19886130.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):399-409 [19072388.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 May;21(5):585-6 [19282771.001]
  • [Cites] Dig Dis Sci. 2010 Jun;55(6):1732-7 [19693667.001]
  • [Cites] Surg Endosc. 2010 Mar;24(3):525-30 [19597776.001]
  • [Cites] Colorectal Dis. 2011 May;13(5):549-54 [20082633.001]
  • [Cites] Dis Colon Rectum. 2010 Feb;53(2):200-12 [20087096.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2007 Apr;17(2):323-39, vi [17556151.001]
  • [Cites] Gastrointest Endosc. 2009 Jun;69(7):1282-7 [19286179.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):675-80 [19251009.001]
  • [Cites] Surgery. 2008 Nov;144(5):786-92 [19081022.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Nov;7(11):1174-6 [19631290.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1007-12 [18594837.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):921-4 [17140899.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1087-93 [19935785.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):454-62 [17704890.001]
  • (PMID = 20703837.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down






Advertisement